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In vitro and in vivo evidence of nephron hypermetabolism in remnant
kidney (RK)—A potential factor in the progression of chronic renal
failure (CRF). D.C.H. Harris, J.I. Shapiro, R.W. Schrier, L. Chan,
Department of Medicine, University of Colorado School of Medicine,
Denver, Colorado. USA. The potential importance to the progression of
CRF of tubular metabolic and structural adaptation to nephron loss has
received little attention. Therefore, determinants of energy metabolism
were examined in isolated perfused and in vivo rat RK 4 weeks after 5/6
nephrectomy and in normal rat kidneys (C). In spite of surgical ablation
of 2/3 of RK mass, viable kidney wt (g) of isolated perfused kidneys
increased to 80% of C, initial glucose production rate to 140%, basal and
total oxygen consumption (Q02) to 100% of C and net sodium reab-
sorption (TNa*) increased to only 40% of C. 31P nuclear magnetic
resonance of in vivo RK and C revealed that ATP synthetic rate (ASR;
mean SEM; 16.2 2.0 vs 10.3 0.9 mol/min/g, P < 0.05) was
higher in RK due to an increase in tissue concentration of inorganic
phosphate (1.17 0.10 vs. 0.82 0.09 moL'g, P <0.05). Intracellular
pH (7.48 0.04 vs. 7.20 0.04, P < 0.001) was higher in RK, whereas
Q02 was similar (3.86 0.45 vs. 4.18 0.32 molJmin/g) and TNa* was
lower in RK than C (117 15 vs. 237 24 mol/minIg, P < 0.001).
Estimated nephron Q02 (4.18 0.32 vs. 1.71 0.13 mol/minhl04
nephrons) and ASR (16.1 2.0 vs. 4.22 0.37 mol/min/l04 nephrons)
were much higher in RK. The lower TNa/Q02 of RK suggests an
inefficiency of sodium transport, or an increase in non-transport pro-
cesses; and the higher ASR/Q02 of RK suggests a change in substrate
preference and/or a relative switch to anaerobic metabolism. The large
increase in nephron Q02 (possibly via oxygen radical production and/or
reduced 02 availability for maintenance of cell viability) and intracel-
lular pH (possibly by activation of enzymes such as phospholipases)
may be crucial to the progressive nature of CRF.
In vitro and in vivo evidence for the reduction of remnant kidney (RK)
hypermetabolism by phosphate restriction (PR), a potential protective
mechanism In chronic renal failure (CRF). D.C.H. Harris, J.I. Shapiro,
R. W. Schrier, L. Chan, Department of Medicine, University of Colo-
rado School of Medicine, Denver, Colorado, USA. Nephron hyper-
metabolism has been demonstrated in RK, and proposed as an impor-
tant factor in the progression of CRF in this model (Kidney mt 31:395,
1986). The protective mechanism of PR in CRF is unknown. Therefore,
the effect of PR on isolated perfused RK hypermetabolism was exam-
ined in rats fed low (LP) or normal phosphate (NP) diet for 4 weeks
following 5/6 nephrectomy. PR reduced oxygen consumption (Q02,
1.81 0.22 vs. 3.05 0.40 moI/min/g, LP vs. NP, P < 0.05), initial
glucose production (GP) rate (0.46 0.04 vs. 0.87 0.12 pmol/minlg,P < 0.02) and final GP but not net sodium reabsorption (TNa*).
Verapamil, which is also protective against progression in RK, had a
similar effect. 31P nuclear magnetic resonance was used to examine the
in vivo effect of PR on pair fed RK rats receiving the phosphate binder
dihydroxyaluminum aminoacetate (DHAAA) or a control glycine-
containing diet (C) for 4 weeks following 5/6 nephrectomy. PR reduced
viable kidney weight (0.82 0,04 vs. 1.10 0.08 g, DHAAA vs. C, P
< 0.01), tissue phosphate (0.59 0.15 vs. 1.69 0.16 mol/g, P <
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0.001), tissue ATP (2.08 0.22 vs. 2.95 0.16 smol/g, P <0.002), ATP
synthesis rate (ASR) and Q02 (4.82 0.49 vs. 7.12 0.87 prnol/min/g,
P < 0.05) but did not change renal blood flow (Q), GRF or TNa (105
22 vs. 107 7mo1/min/g). The glycine of DHAAA and C raised in vivo
Q and Q02 compared to RK rats fed normal chow. Thus, PR reduced
RK compensatory renal growth, sodium-transport independent Q02
and ASR, an effect mediated by the reduction of Pi. It is proposed that
this reduction in Q02, possibly by a concomitant reduction in 02 radical
formation, may be critical to the protective effect of PR in this model of
CRF.
Effect of blood pressure treatment with an angiotensin converting
enzyme (ACE) inhibitor or Ca + inhibitor on the evolution of renal
injury in the rat. B. Jackson, L. Debrevi, R. Cubela, M. Whitty, C.!.
Johnston, Department of Medicine, Melbourne University, Austin
Hospital, Heidelberg, Victoria, Australia. The subtotal nephrectomy
(Nx) and streptozotocin induced diabetes mellitus (DM) models of renal
injury were established in rats, and the effect of chronic treatment with
an ACE inhibitor or a Ca inhibitor on the evolution of renal injury
compared with that in untreated animals. Nx rats were treated with
enalapril (E, 5mg/kg/day, N = 11), felodipine (F, 30 mg/kg/day, N = 11)
or untreated (C, N 18). Systolic blood pressure (SBP) was lowered
equally over five weeks by each treatment (176 7, C; 122 5, E; 128
3, F). Plasma creatinine (molIl) was lower (P < 0.05) with E (110
8) than C or F (173 19, 153 27), as was proteinuria (mg/24 hr, E, 15
3, P < 0.001; C, 85 22; F, 221 35) and glomerulosclerosis. DM
rats were treated with enalapril (E, N = 17) or verapamil (V, 5
mg/kg/day, N = 17). Blood glucose was maintained at 20 mmoiIl in all
diabetic rats by subcutaneous insulin. SBP was lowered equally over
two months by each treatment (131 3,untreated diabetic controls; 108
2, E; 114 2, V). Creatinine clearance (Cr Cl ml/min) in diabetic rats
was increased compared with non-diabetic controls (1.52 0.06 vs.
1.15 0.05, N = 11, P <0.01). E but not V reduced the elevated CrC!
of diabetic rats (E, 1.37 0.07, P <0.01; V, 1.49 0.05). Proteinuria
was reduced by E but not V treatment (E 36 3, P < 0.05; untreated
diabetes 71 18; V, 58 10; non-diabetic controls 7.4 0.5). ACE
inhibitor, but not Ca + inhibitor, treatment increased effective renal
plasma flow (iodohippurate clearance) in both Nx and DM groups.
Treatment with an ACE inhibitor or a Ca + inhibitor had similar effects
on systemic blood pressure in two models of progressive renal disease.
Only the ACE inhibitor reduced the degree of renal injury.
Angiotensin II and the renal sympathetic nerves act independently on
tubular sodium reabsorption. S. Pincus, P.J. Harris, Department of
Physiology, University of Melbourne, Parkville, Victoria, Australia.
The renin-angiotensin system and the renal sympathetic nerves have
powerful effects on renal sodium excretion, via their actions on both
renal haemodynamics and renal tubular transport. To determine whether
these systems are interdependent, mean arterial pressure (MAP), urine
flow rate (UFR) and sodium excretion (UNaV) were measured during 60
minute periods in euvolaemic, anaesthetized rats (Group 1), following
denervation (DNx) and during subsequent converting enzyme inhibition





Group 1 (N = 8) treatment DNx DNx + CEI
MAPmmHg 125±3 115±3a 942a.b
UFR .t1/min 3.12 0,5 5.33 1.0 6.65 1.7
UNaV nmol/min 213 61 531 iiia 884 184a,b
Group 2 (N = 13)
Pre-
treatment CE! CE! + DNx
MAP mmHg 132±2 118±3a 973a,b
UFR 1iJ/mjn 4.17 0.49 5.09 0.62a 7.46 097a,b
UNIV nmol/min 239 61 583 119 1418 314a,b
Mean SEM. a P <0.05 compared with pre-treatment
b cf DNx or CE!. Excretion data for left kidney
Converting enzyme inhibition resulted in a similar degree of natriure-
sis in innervated and denervated kidneys. Similarly, the extent of
denervation natriuresis was unaffected by converting enzyme blockade.
Thus the renin-angiotensin system and the renal sympathetic nerves
appear to have independent actions on renal sodium excretion. !n 6
animals from Group 2 clearance measurements of renal haemodynamics
indicated that natriuresis either by CEL or denervation occurred without
demonstrable changes in filtered load but with a significant increase in
fractional sodium excretion. This suggests that these effects involve
direct but independent actions on the tubular reabsorption of sodium.
Effect of oral urea therapy in experimental Inappropriate ADB secre-
tion (SIADH). M.J. Field, J.R. Lawrence, Department of Medicine,
University of Sydney, Concord Hospital, N.S. W., Australia, Treatment
with urea has been reported to improve hyponatraemia in the clinical
syndrome of S!ADH. To investigate the mechanism, we established an
animal model of the syndrome, and evaluated the effect of oral urea
therapy on sodium and water balance. Male Wistar rats were treated
continuously with exogenous arginine vasopressin (ADH) at 1 U/day,
by a subcutaneous osmotic minipump. I.P. water was given daily (2.5%
dextrose, 7.5% of body weight), and a four-day balance study per-
formed. A "Control" group received water loading only, Animals
receiving ADH but no urea ("SIADH" group) developed severe and
progressive hyponatraemia: plasma Na was 123 2 mM/liter on day 2,
117 3 mM/liter on day 4 (means SEM, N = 10). Another group
("Urea") was treated with ADH in the same way, but on days 3 and 4
these rats were given urea, 100 mg/tOO g body weight, in the food. P1
Na was 125 1 mM/liter on day 2 and 134 2 mM/liter on day 4 (P <
0.001 compared to SIADH on this day). In controls, p1 Na was 145—155
mM/liter throughout. Daily urine volumes were not different between
SIADH and Urea groups. However, while a small rise in daily Na
excretion occurred between days 1—2 and 3—4 in SIADH animals (+0.4
0.2 mmol/day), a similar fall occurred in the Urea group (—0.3 0.2
mmol/day) (P < 0.05). We conclude that hyponatraemia is ameliorated
by oral urea treatment in this model of SIADH; the mechanism involves
enhancement of renal Na conservation, possibly by an effect on Na
efilux from the loop of Henle.
Evidence for a voltage-dependent acidification defect in the distal renal
tubular acidosis (dRTA) of mineralocorticoid deficiency. G.G. Allen,
L.M. Van der Wielen, L.J. Barratt, Renal Unit, Flinders Medical
Centre, Bedford Park, South Australia, Australia. Some forms of
hyperkalemic dRTA appear to be due to a voltage-dependent acidifica-
tion defect in the cortical collecting tubule (CCT). We have demon-
strated previously such a defect in amiloride-induced dRTA in rats. The
present study examines the mechanism of dRTA in chronic mineralo-
corticoid deficiency in rats by determining the effects of adrenalectomy
(Adx) on urine acidification and on the potential difference (pd) of
CCT's under conditions favouring maximal distal proton secretion, viz.
during the infusion of 4% sodium sulphate at 2 mI/hr in both intact and
Adx animals. Intact animals achieved a minimum urine pH of 5.8 0.1
(N = 12) c.f. 6.3 0.1 (N = 16) in Adx animals (P < 0.001) while the
pd in CCT's of the same animals was —45.9 3.0 mV (N = 21) and
—19.1 2.3 mY (N = 22) respectively (P < 0.001). Subsequent
experiments were performed to determine whether amiloride (Am)
would induce an additional voltage-dependent acidification defect in
Adx animals. During Am infusion minimum urine pH increased to 6.8
0.1 (N = 15) (P < 0.01) while the pd in CCT's fell to —1.7 0.7 mV (N
= 27) (P < 0.001). Conclusions: (1) Adx induces a significant acidifica-
tion defect associated with reduced pd's in CCT's. (2) Am induces a
super-added acidification defect associated with a further reduction in
the pd of CCT's. (3) These data support a voltage-dependent mecha-
nism operating in CCT's to explain the dRTA induced by both Adx and
Adx+Am.
The metabolism of C3 and C4 in patients with lupus glomerulonephri-
tis. J.A. Charlesworth, B.A. Pussell, J. Golding, P.W. Peake, V.
Timmermans, D. Wakefield, Departments of Medicine and Pathology,
Prince Henry Hospital and the University of N.S. W., Sydney, Austra-
lia. The metabolic behaviour of purified functionally-active human C3
and C4 was examined in 14 patients with systemic lupus erythematosus
(SLE) and biopsy-proven glomerulonephritis (GN), 10 patients with
uncomplicated infection (endocarditis, infectious mononucleosis and
hepatitis-B) and 14 healthy controls. The project was designed to define
differences in complement behaviour between patients with and without
immune complex-mediated tissue damage. All patients had elevated
levels of circulating immune complexes (CIC) and nine of the SLE
group had one or more null alleles at the C4A and/or C4B genetic loci.
The majority of this group were also hypocomplementemic. There was
a comparable increase in fractional catabolic rate (FCR) in the two
patient groups—SLE: 2.85 0.7%/hr (Mean SD); infection: 2.92
0.55%/hr; controls: 1.87 0.17%/hr. C4 synthesis rates were 0.25
0.16; 0.37 0.14 and 0.28 0.15 mg/kg/hr, respectively. The FCR of
'311.C3 was also elevated—SLE: 2.15 0.5; infection: 2.22 0.17 and
controls: 1.6 0.15%/hr. C3 synthetic rates were 0.65 0.2, 0.92
0.25and 0.53 0.13mg/kg/hr respectively. Studies of purified C4A3,B0
and C4AO,B I showed that these preparations had metabolic character-
istics comparable to those of the common C4A3,B 1 protein. There was
a significant correlation between FRC-C4 and C4 synthesis in patients
with infection (r = 0.71; P < 0.01). In contrast, an inverse correlation
was observed with the SLE group (r =
—0.72; P < 0.01). The group
with infection also showed a correlation between FCR-C3 and C3
synthesis (P < 0.05) but no correlation was observed in the group with
SLE. We conclude that patients with lupus nephritis show an impaired
complement synthetic response in the presence of an immune complex
stimulus to the classical pathway. This could influence effective processing
of an immune complex load and lead to enhancement of tissue injury.
The production of reactive oxygen species by intraglomerular mono-
cytes in experimental glomerulonephritls N. W. Boyce, P.G. Tipping,
S.R. Holdsworth, Department of Medicine, Prince Henry's Hospital,
Melbourne, Australia. A macrophage-dependent model of diffuse pro-
liferative glomerulonephritis was induced in rabbits by anti-GBM
antibody administration. Animals were studied at the time of maximal
glomerular macrophage accumulation (Day 6). Intraglomerular mono-
cytes (glom m4) were obtained from the cellular outgrowth of macro-
phage infiltrated nephritic glomeruli by adherence techniques after
short-term (60 minute) culture of isolated diseased glomeruli, Control
adherent monocyte populations were simultaneously obtained from
peripheral blood (blood m4) and lung lavage fluid (alveolar m4).
Superoxide anion (Oz) and hydroxyl radical (OH) production were
assessed using the superoxide dismutase reduction of ferricytochrome
C and deoxyribose oxidation techniques respectively. Glom m4 pro-
duction of 0 (27.4 3.1 nM02/hr/l06 cells) and OH (32.2 1.4
units/hr/tO6 cells) were both significantly greater that the production of
reactive oxygen species seen with control monocyte populations [02
(nM/hr/106 cells): blood m = 15.8 1.3; alveolar m = 16.2 1.7and
OH (units/hr/tO6 cells): blood m4 14.3 1.8; alveolar mfr = 16.2 2,0
(all p < 0.01 cf, glom md.')l. Thus infiltrating monocyte/macrophages
within nephritic glomeruli represent a locally activated monocyte
population which produce toxic oxygen moieties capable of contribut-
ing to macrophage mediated glomerular injury.
Procoagulant activity of Isolated glomerular macrophages in experi-
mental glomerulonephritis. PG. Tipping, S.R. Holdsworth, Monash
University Department of Medicine, Prince Henry's Hospital, Mel-
bourne, Australia. Glomerular procoagulant activity (PCA) is aug-
mented in macrophage dependent models of glomerulonephritis (GN),
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but not in models where glomerular injury is macrophage independent.
Previous studies have suggested a role for augmented PCA in the
initiation of glomerular fibrin deposition. The cellular source of this
augmented PCA is unknown, although glomerular macrophages are
likely candidates. In order to study the expression of PCA by infiltrating
glomerular macrophages, a technique (involving graded sieving and
short-term glomerular culture) was developed which allowed isolation
of 4.8 x l0 macrophages, within 90 minutes of sacrifice, from rabbits
developing anti-glomerular basement membrane antibody-induced ON.
These macrophages were characterized by morphological and func-
tional criteria. They expressed markedly augmented PCA (2.8 0.7
mU/103 cells) compared to peripheral blood monocytes (0.05 mU/l03
cells) and alveolar macrophages (0.09 0.02 ,Ji0 cells) isolated from
the same rabbits under similar conditions. The PCA of isolated glomer-
ular macrophages had the same functional characteristics as the PCA of
sonicated whole glomeruli, and was consistent with the characteristics
of tissue factor. These studies show that glomerular macrophages
express augmented PCA, indicating they are functionally activated.
Glomerular macrophage PCA may contribute significantly to the aug-
mented glomerular PCA in this fibrin related model of GN, and may be
the trigger for macrophage-initiated glomerular fibrin deposition.
Tubular-antigen associated renal disease in New Zealand white rabbits
(NZWR): II. Investigation of mediators of glomerular injury. Localiza-
tion and characterization of the glomerular capillary wall antigen. T.J.
Neale, N. Boyce, N. Fernando, J.C. Muir, M.J. Nicol, S.R. Holds-
worth, Department of Medicine, Wellington School of Medicine,
Wellington, New Zealand, and Department of Medicine, Prince Hen-
ry's Hospital, Melbourne, Australia. We have produced glomerulone-
phritis (GN) in NZWR with sheep anti-FxlA globulin (SAFG) (C/in Exp
Immunol 63:629, 1986), characterized by granular glomerular capillary
wall (GCW) immunofluorescence (IF), small subepithelial deposits,
peak binding of globulin at 24 hrs, and proteinuria maximal at 48 hrs.
NZWR immunized with autologous FxlA developed tubulo-interstitial
disease. Mediation of the glomerular lesion was examined by treatment
with cobra venom factor (CVF) and nitrogen mustard (NM). SAFG
binding and proteinuria were independent of complement or leucocytes
(Table I) but dose-dependent (Table 2). SAFG reacted in dot blot with
a deoxycholate extract of rabbit glomeruli. Molecular weights of the
reactants were determined by PAGE and immunoblot. Immunogold
EM of kidney from rabbits injected with SAFG revealed reactivity with
discrete components of glomerular visceral epithelium and endothelium
and laininae rarae. Proteinuria in this model is mediated by antibody
without requirement for complement or leucocytes. The putative anti-
gen(s) is/are associated with components of the GCW which share
epitopes with autologous tubular FxlA. This model is an example of an




group P mg/ml mg/24 hrs
NSG 10 0.15 SD 0.02 11.8 SD 4.0
SAFG 16 0.22 SD 0.03 17.8 SD 1.4
NM/SAFG 8 0.37 SD 0.08 18.0 SD 3.1
CVF/SAFG 12 0.32 SD 0.07 23.7 SD 2.6
Table 2. SAFO dose response at 24 hrs
Dose Kidney binding Proteinuria
mg/kg pg/g mg/24 hrs
1.6 0.27 SD 0.03 —
10 3.6 SD 0.21 17.8 SD 1.4
30 11.35 SD 1.2 45 SD 10
Predominance of lambda light chain IgA production in IgA nephrop-
athy. K.N. Lai, F.M. Lai, S.H. Chui, C. W. Lam, Departments of
Medicine and Chemical Pathology, Chinese University of Hong Kong,
Hong Kong. The immunochemical nature of the light chains of the
mesangial IgA deposits were studied in 13 IgA nephritic patients with
only IgA isotype in their renal biopsies. Direct immunofluorescence
(IF) using rabbit and goat anti-human monospecific antibodies demon-
strated lambda (A) light chain IF in all 13 biopsies (100%). Kappa (K)
light chain IF was detected in 10 renal biopsies by the rabbit anti-human
anti-sera and in 8 renal biopsies by the goat anti-human anti-sera.
Monoclonal antibodies studies showed lambda IF in all 13 biopsies and
kappa IF in 8 biopsies. Twelve biopsies showed a predominance of
lambda light chain IF staining in the mesangial deposits. Double
immunofluorescence technique with anti-human alpha heavy chain
anti-serum and anti-human light chain anti-sera confirmed that the light
chains IF arose directly from the IgA deposits. The K/A ratios of serum
immunoglobulin (mean SD) in 30 patients and 32 controls were
studied by an ELISA method:
N IgA IgG 1gM
Controls 32 1.2 0.24 2.2 0.22 1.2 0.45
IgA nephropathy 30 0.9 0.17 1.9 0.50 1.5 0.41
P value <0.001 <0.01 <0.01
The K/A ratio of IgA from in vitro lymphocyte culture was reversed in
patients (P < 0.01) but not in controls. Our results indicate that
although IgA antibody production in IgA nephropathy is polyclonal, a
unique antigenic stimulus leading to excessive production of lambda
light chain containing IgA is demonstrated.
Short-term controlled trial of cyclosporine A therapy in IgA nephrop-
athy. K.N. Lai, F.M. Lai, J. Va/lance-Owen, Departments of Medicine
and Morbid Anatomy, Chinese University of Hong Kong, Hong Kong.
A randomized prospective study of 19 patients with IgA nephropathy
and significant proteinuria (>1.5 g/day) was conducted to determine the
therapeutic value of cyclosporine A. The patients were divided into two
groups: Group A, 9 patients receiving oral cyclosporine A (5 mg/kg/day)
for 12 weeks; and Group B, 10 patients receiving placebo (0.05
mI/kg/day) and acting as controls. The two groups were comparable in
age of presentation, sex ratio, serum creatinine, creatinine clearance,
daily urinary protein excretion, severity of renal histopathologic
changes, and incidence of hypertension but the Group A patients had
higher serum IgA levels (P < 0.05). Although the plasma cyclosporine
A levels were maintained within a narrow therapeutic range, a signifi-
cant rise of serum creatinine (P < 0.01) and a fall in creatinine clearance
(P < 0.01) was demonstrated in Group A patients after 6 weeks'
therapy. A significant reduction of proteinuria (P < 0.02) and an
increase of serum albumin concentration (P < 0.02) was observed.
Serum IgA levels were reduced in 7 patients. Renal functions improved
within 8 weeks after cessation of therapy. Proteinuria remained less
than 50% of pre-treatment values in 33% of the patients. No similar
biochemical changes were observed in the controls. Our findings
suggest that short-term cyclosporine A therapy may be beneficial in
reducing proteinuria in some patients with IgA nephropathy. As tran-
sient renal impairment is not infrequently observed despite mainte-
nance of a narrow therapeutic plasma level, its indiscriminate use in
glomerulonephritis should be discouraged.
Resistance of urinary tract isolates of escherichia coil to co-trimoxazole,
sulphonamide, trimethoprim and ampicillin: an 11-year survey. B.A.
Peddie, R.R. Bailey, fE. Wells, Department of Nephrology,
Christchurch Hospital, and Biostatistics Unit, Christchurch School of
Medicine, Christchurch, New Zealand. Since the introduction of tn-
methoprim (TMP) alone as an antimicrobial agent for the treatment of
urinary tract infection there has been concern that resistance to TMP
would rise as its use increases. The susceptibility of urinary tract
Escherichia (E) coil isolates to co-trimoxazole, sulphonamide, TMP
and ampicillin was monitored from January 1975 to December 1985. A
total of 1908 isolates were obtained from patients enrolled in various
clinical trials. During this study 65 (3.4%) of the 1908 isolates of E coli
were resistant to TMP, while a further 14 (0.7%) were of intermediate
sensitivity. Of the 1747 isolates from outpatients 52 (3%) were resistant
to TMP, compared with 13(8.1%) of 161 from hospitalized patients. The
respective numbers of isolates with intermediate sensitivity to TMP
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were 12 (0.7%) and 2 (1.2%). In 1975 no trimethoprim-resistant strains
of E coil were isolated in our laboratory, while in 1985 the resistance
rate was 7.3%. A statistically significant trend of increasing resistance
to co-trimoxazole and TMP was observed, but there was no comparable
alteration in sulphonamide resistance. Ampicillin resistance was 21% in
1975 and continued to rise significantly to 31% at the end of the survey
period. Our experience would appear to be paralleling that in England
and Finland, although TMP and co-trimoxazole continue to perform
better than ampicillin, for which the percentage of resistant E coli is
unacceptably high. However it could also be concluded that TMP and
co-trimoxazole have retained their competitive position among drugs in
popular use for the treatment of urinary tract infections in spite of heavy
prescribing.
Association between diaphragm use and asymptomatic bacteriuria.
R.R. Bailey, B.A. Peddie, V.A. Bishop, E.A. Blake, S.!. Gorrie, D.
Edwards, Department of Nephrology, Christchurch Hospital, and
Chrjstchurch Branch, New Zealand Family Planning Association,
Christchurch, New Zealand. A previous study in this department
demonstrated that diaphragm-users had a higher prevalence of gram-
negative bacilli in their vaginal swabs than women using intra-uterine
contraceptive devices (IUCDs), oral contraceptives (OCs) or no con-
traception (nil). Gram-positive cocci were more often isolated from the
vaginal swabs of IUCD-users. A prospective study was carried out to
assess the association between asymptomatic bacteriuria (bacterial
count in mid-stream urine >100 x l06/liter) and contraceptive method.
Urine specimens from 320 women were cultured, 80 in each of the
following groups: diaphragm, IUCD, OC, and nil. All methods had been
practised for at least one year. Asymptomatic bacteriuria was found in
the following women:
Diaphragm — 12 (all E coli)
IUCD — 3 (E coli, P mirabilis; S saprophyticus)
OC — 5 (all E coli)
Nil — 4 (3 E coli, 1 S saprophyticus)
Women using diaphragms had a significantly higher incidence of asymp-
tomatic gram-negative bacteriuria (X2 = 9.01; P < 0.05). No increase in
gram-positive bacteriuria was noted in IUCD-users. Factors such as
parity, number of sexual partners and frequency of intercourse had no
apparent effect on the prevalence of asymptomatic bacteriuria. These
findings suggest that the use of diaphragms for contraceptive purposes
may contribute to the risk of urinary tract infections in sexually active
women.
Combined treatment with vitamin D and keto acids (KA)—A new
treatment for renal osteodystrophy. P. T. Frohiing, F. Kokot, K. Vetter,
I. Kaschube, R. Schmicker, I. Grossmann, K. Lindenau, St. Josefs
Hospital, Potsdam, GDR. Thirty-five patients with advanced renal
failure were treated with low protein diet (0.4 g/kg b.w.), KA substitu-
tion and vitamin D. Fifty-two patients on the same diet were treated
with vitamin D only, and 12 untreated uremics served as a control
group. Calcium, inorganic phosphate, intact P'FH, 25-OH-D, calcitonin,




OF OM OF + OM
0 0 1Controls 11
Vit. D only 3 0 27 22
Vit.D+KA 24 0 4 7

















Controls 10.2 2.53 11.1 262 6.1 8.0
Vit.Donly 11.7 1.56 71.1 663 5.6 9.4
Vit. D ÷ KA 11.5 0,96 74.6 756 4.8 9.2
This combined therapy can diminish hyperparathyroidism and improve
bone mineralization in spite of advanced renal failure, and it can be
recommended for the prevention of renal osteodystrophy.
Pregnancy in women with membranous glomerulonephritls. D.K.
Packha,n, R.A. North, F.K, Fairley, J.A. Whitworth, P. Kincaid-
Smith, Department of Nephroiogy, Royal Melbourne Hospital,
Victoria, Australia. Thirty-three pregnancies in 24 patients with mem-
branous glomerulonephritis were analyzed to assess the effect of
pregnancy on mother and fetus. Eight pregnancies (24%) resulted in
foetal loss, 6 in the first trimester. Fourteen (43%) infants were
premature. Seven out of 20 (33%) were small for gestation age. Three
(12%) patients developed impaired renal function. One had prior mildly
impaired function. Hypertension developed in 15 patients (46%). None
had been previously hypertensive. In all, bar one, significant protein-
una was recorded. In 10 pregnancies (30%) in 7 women nephrotic
proteinuria (>5 gm protein/24 hr) was detected. Eighteen out of 22
(55%) other pregnancies showed increased proteinuria. Following preg-
nancy 2 (8%) patients had impaired renal function, one of whom had
prior normal function. In 3 (9%) pregnancies hypertension failed to
resolve post partum and in 6 (18%) increased proteinuria persisted post
partum. Nephrotic proteinuria in the first trimester correlated with both
poor foetal and maternal outcome (p = 0.0004 and p = 0.0002
respectively, using Fishers exact test). Thus pregnancy in patients with
membranous glomerulonephritis is associated with increased foetal
loss. A significant number of women have renal complications during
pregnancy and in some these persist post partum. Nephrotic proteinuria
in the first trimester is a poor prognostic sign.
Successful outcome of pregnancies associated with advanced renal
impairment and the use of hemodialysis. M.C. Falk, J.S. Horvath, D.J.
Tiller, A.F. Phippard, A. Korda, A. Child, M. O'Connor, Department
of Renal Medicine, Royal Prince Alfred Hospital, Camperdown,
N.S.W., Australia. The results of pregnancy in women with advanced
renal impairment has generally been unfavorable. Four women, all of
whom had creatinine clearances below 30 mI/mm were supported by
hemodialysis during pregnancy in order to improve fetal survival. Their
mean age was 23 (range 18 to 30). Three had reflux nephropathy
complicated by multiple urinary tract infections and one had diabetic
nephropathy. The patients had serum creatinines >300 mol/liter
(range 300 to 385). The 24 hour urine protein excretion was >2 g in all
patients (range 2.05 to 3.34). Dialysis was commenced using bicarbon-
ate hemodialysis for 4 hours, 4 times a week at 14, 20, 28 and 30 weeks
gestation. Elective caesarian sections were undertaken in each patient
at 32 weeks. The mean birth weight was 1.57 0.48 kg. The birth
apgars for the three reflux nephropathy patients were >5 at 1 minute
and >7 at 5 minutes and cord pH >7.27. The infant whose mother had
IDDM and was dialysed for two weeks had a cord pH of 6.83 and apgar
scores of 0, 3, 8 at 1, 5, 10 minutes. All infants had evidence of hyaline
membrane disease. However, two infants, including the one whose
mother was diabetic, required ventilation for 7 and 10 days. These 4
women with advanced renal impairment successfully delivered live
infants, These infants had normal milestones at one year. One mother
has developed end-stage renal failure two years after dialysis. Despite
the absence of control groups and the small numbers, these results
suggest the safety and efficacy of hemodialysis in pregnancy with
advanced renal failure.
Renal and myocardlal infarcts associated with SLE and the lupus
inhibitor. P. Boyle, F. Craswell, C. Hawley, J. Searle, Departments of
Nephrology and Pathology, Royal Brisbane Hospital, Brisbane, Aus-
tralia. We describe 3 patients with arterial thrombosis associated with
acute SLE and the lupus inhibitor. Two patients developed acute
reversible renal failure, with multiple infarcts on renal biopsy.
Thromboses involved small arteries without evidence of vasculitis.
Glomerular disease was not severe and there were no glomerular
capillary thromboses. The third patient developed acute fatal myocar-
dial infarction in the setting of acute SLE, and had multiple coronary
thromboses without vasculitis or atheroma. Widespread thrombi were
also seen in renal arterioles. The association of lupus inhibitor with
thrombosis is now well recognized. Most thromboses are venous.
Arterial thromboses, when described, have almost always involved the
cerebral vasculature. Similar mechanisms seem to be responsible for
Abstracts 133
the marked foetal wastage associated with the lupus inhibitor. While
steroid treatment may result in the disappearance of the lupus inhibitor,
the optimum treatment is not established and may differ from the
treatment usually given for acute SLE crises. Anticoagulation,
prostacyclin, or plasmapheresis may be indicated. Differentiation may
be difficult between thromboses induced by lupus inhibitor and TTP
complicating SLE. Renal infarction should be added to the differential
diagnosis of patients with SLE and acute renal failure.
The New Zealand glomerulonephritis survey. L.C. Williams, S.F.
Hannan, on behalf of the New Zealand Nephroiogists and Renal
Pathologists, Department of Medicine, Auckland Hospital, Auckland,
New Zealand. The survey began in 1972 as a nationwide prospective
study of biopsy-proven primary GN in adults. Enrolment ended in
mid-1983 and preliminary results were presented in 1985. Because there
were differences in diagnostic patterns both within and between cities
over the 11 years, a complete revision of all the cases has been made.
The pathologic material was reviewed independently by K.E. Holley
assisted by J.V. Donadio who also began the clinical data review. The
1982 classification of Churg and Sobin was used by the Mayo Clinic
team. By this return to the original material many missed cases were
found and, since original clinical data were still available, put into the
study. This was not possible in one city where a minority of those
eligible had been notified, and contemporaneous data did not exist. That
city has been omitted so that the survey now covers 84% of the
1,822,300 total adult population. For Polynesians the coverage is
reduced to 74.5% of the 182,900 adults. Despite these deletions the
number of cases is up to 868. Differences between centers, both in
overall incidence and in the relative importance of the various sub-types
of GN, are found to persist after exclusion of any systematic variation
in diagnostic practices. IgA disease remains the most frequent diagnos-
tic group (131 cases). There has been an increase in the ranking of FSGS
and a decline in focal GN. Most of the variations between original and
revised diagnoses were predictable, e.g. an interchange of cases be-
tween IgA and mesangial-proliferative GN.
Role of hyperparathyroidism in hormonal disorders of patients with
chronic renal insufficiency. K. Lindenau, F. Kokot, K. Vetter, E.
Blanck, R. Schmicker, K.-H. Gotz, L. Meyer, P.T. Frohling, Depart-
ment of Internal Medicine, District Hospital, Potsdam, GDR. Hyper-
parathyroidism has a key role in endocrine disorders of patients with
chronic renal failure. The hormonal status was investigated in 109
patients under ONT (low protein diet plus keto acids [KAI), 127
patients on hemodialysis (RDT) and 42 patients after kidney transplan-
tation (KT). The analysis by RIA technique of the following hormones
served as control parameters: Parathyroid hormone (PTH), 25-OH-D,
calcitonin (CT), insulin (IRI), growth hormone (HGH), prolactin (PRL),
gastrin (GA), testosterone (TE), foll.stim. hormone (FSH), luteinis
hormone (LH) and glucagon (GLU).
Results (mean value):
PTH CT PRL GA IRI TE Creatinine
ng/ml pg/mi ng/ml pg/mi jsU/iiter ng/ml mg/dl
Normal values 0.60 94 5.0 50 15.0 4.0—7.0 1.2
ONT 0.86 410 31.8 81 27.1 5.1 10.4
RDT 2.40 395 39.5 131 42.0 2.3 12.8
KT 1.28 684 14.9 105 29.6 3.5 2.1
The other hormones do not show significant differences. The better
control of hyperparathyroidism in patients on ONT is responsible for
the diminishing of the disorders of other hormones, too. Some hor-
monal disorders persisted after KT if PTH could not be normalized.
The effect of cytotoxic antibodies and HLA B + DR matching on
cadaveric graft survival. J.J.B. Petrie, R.J. Rigby, D.R. Wall, R.W.
Strong, N. Strachan, I.R. Hardie, Renal Transplant Unit and Depart-
ment of Immunology, Princess Alexandra Hospital, Brisbane, Austra-
lia. The effect of cytotoxic antibodies on graft survival was examined in
354 cadaveric transplants performed at the Princess Alexandra Hospital
in the period 1/1/82 to 31/12/86. 176 received azathioprine/prednisolone
as initial therapy, while in 178 initial therapy included cyclosporine. All
recipients had been transfused. In 285 recipients (254 tjrst graft, 29
second graft, and 2 third graft) there were no cytotoxic antibodies
present in the serum at the time of transplantation. One-year graft
survival in this group was 82% 2%. In 69 recipients (42 first grafts, 24
second grafts, and 3 third grafts) the serum at the time of transplantation
contained antibodies cytotoxic to T cells reactive with 5% or more of
the test panel. One-year graft survival in this group was 60% 8%,
significantly worse than in the group without antibodies (P < 0.001). A
similar result was obtained when analysis was confined to first cadaver
graft recipients. The deleterious effect of persistent sensitization was
seen both in patients treated with cyclosporin A and those treated with
conventional therapy. In 55 patients (40 first grafts, 13 second grafts,
and 2 third grafts) antibodies were absent at the time of grafting, but
historical sera contained cytotoxic antibodies reactive with 30% or
more of the test panel. One-year graft survival in this group was 75%
8%. Thus, provided antibodies were lost by the time of transplantation,
their presence in the past did not seem to have a major adverse effect on
graft outcome. The effect of matching for B + DR antigens was
examined. In 116 unsensitized patients with 1 or zero B + DR
mismatches, one-year graft survival was 86% 4%. In 169 unsensitized
patients with 2 or more B + DR mismatches, one-year graft survival
was 80% 4%. This trend to better results in the better matched
patients was not significant (P > 0.5), and was confined to those
patients treated with conventional immunosuppression. In 28 of the
recipients sensitized at the time of grafting, the B + DR mismatch was
I or zero and graft survival was 77% 9%. In 41 of the sensitized
patients, the B + DR mismatch was 2 or more. Graft survival in this
subgroup was 47% 15%. Despite the small numbers involved, this
30% difference was significant (P < 0.025). Our results suggest that for
patients with continuing sensitization, it is important that a well-
matched kidney be transplanted. In unsensitized patients, matching
appears to be less critical, particularly where cyclosporine A is used as
an initial therapy.
A simple technique which markedly reduces the incidence of peritonitis
in CAPD. J. Moran, A. Heazlewood, J. Andrew, J. Niall, St. Vincent's
Hospital, Melbourne, Australia. Our CAPD experience since 1978
(177.4 patient years) has shown poor results with both Travenol System
I and System II. The incidence of peritonitis in patients using System I
has remained high over the entire 9 years (1 episode per 7.7 patient
months) with little fluctuation. When the System II (which has a Luer
lock connection) was introduced in 1984 a worsening of the peritonitis
rate was noted; the mean peritonitis rate in our Unit with this system is
1 episode per 5.5 months. The introduction of a simple technique in
which the patient sprays the female end of the System II Luer lock with
70% ethanol prior to bag connection markedly improved the peritonitis
rate (1 episode per 14.1 patient months). The results using systems in
which there is ultraviolet sterilization of the System I connection
(Travenol System III and UVXD) were also markedly better (peritonitis
rate I episode per 15.3 patient months). It is clear that CAPD results can
be improved by either ultraviolet or ethanol sterilization of the connection.
The latter has the advantages of being cheap, simple and easy to learn.
Peritonitis rate
No. of episode per
episodes of Patient patient
peritonitis months months
System I 197 1518 7.7
System II 26 143 5.5
System H with ethanol spray 18 254 14.1
System III or UVXD 14 214 15.3
CAPD peritonitis associated with bowel pathology. M. Kwong, C.
Wood, D. Scott, R,C. Atkins, N.M. Thomson, Department of Nephroi-
ogy, Prince Henry's Hospital, Melbourne, Australia. In patients on
CAPD, peritonitis due to bowel pathology is thought to have a poor
prognosis. Bowel pathology is suspected if multiple organisms are
isolated. This analyzes the types of bowel pathology causing peritonitis
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in our CAPD program, the profile of organisms isolated and subsequent
patient outcome. From June 1978 to November 1986, 743 episodes of
peritonitis have occurred in 225 patients on CAPD. Multiple organisms
(2 or more) have been isolated from dialysate on 83 occasions (11.2%)
and 3 or more organisms on 19 occasions (2.6%). Bowel pathology was
identified as the cause of 16 episodes of peritonitis occurring in 15
patients (7 female, 8 male), aged 16—68 years (mean 49.8). Three
organisms or more were isolated in 11 of these 16 episodes (range 1—4:
mean 3.3). The organisms were mainly gram negative bowel flora (N =
31), Staphylococci (N = 9), anaerobes (N = 7) andfungi (N = 3). Bowel
pathology included diverticular abscess (N = 5), appendicitis (N 3),
perforation/infarction (N 5) and cholecystitis (N 12). Patient age,
duration of CAPD and degree of fever, leucocytosis and dialysate white
cell count did not assist the initial diagnosis of underlying bowel
pathology. Four patients died (uncontrollable sepsis), 9 were trans-
ferred to hemodialysis and 2 continued with CAPD. This study confirms
the poor patient survival and CAPD technique survival following episodes
of peritonitis secondary to bowel pathology. Diagnosis is suggested
primarily by the isolation of multiple organisms, especially 3 or more.
Investigation of the expression of and Immune responses to glomerular
epithelial cell intermediate filament vimentin in human and experimental
glomerular disease. T.J. Neale, J.C. Muir, R. Drake, H. Baird, Depart-
ment of Medicine, Wellington School of Medicine, Wellington, New
Zealand. Vimentin (vmn), a 58Kd cytoskeletal intermediate filament
protein (6-11 nm) is expressed on glornerular visceral epithelial cells.
Vmn expression in 218 human renal biopsies and in experimental
glomerular diseases in rats was assessed, by indirect IF using mono-
clonal anti-vmn antibody. Striking alterations in vmn distribution were
observed in crescentic UN, membranous nephropathy, proliferative
GN, FGS, IgA disease and diabetic nephropathy, Sequential biopsies of
rats developing aminonucleoside nephrosis, adriamycin nephropathy,
anti-GBM antibody disease and Heymann's nephritis indicated distur-
bances in vmn expression prece4d, or occurred concurrently with
proteinuria. Minimal changes in vmn distribution followed oral
colchicine treatment of normal rats but proteinuria was reduced in
normal and Heymann's nephritic rats. The sera of 114 normal blood
donors, 52 renal transplant, 100 nephritic and 50 miscellaneous patients
with renal disease were assayed for anti-vmn antibody on colchicine-
treated Hep-2 fibroblasts, Normals (15%), miscellaneous non-nephritic
renal patients (18%) and renal transplant patients (62%) made a-vmn
antibody. GN patients made a-vmn antibody in 67% showing striking
segregation to FGS (82%), minimal change (78%) and IgA disease
(50%). However, positive sera showed no or equivocal staining on
human glomerular epithelial cells. Perturbations in vmn expression are
a marker of glomerular injury; disturbances in vmn integrity may
preede functional injury. Nephritic patients develop antibody to vmn but
our data do not allow the conclusion that such antibody is pathogenetic.
Blood rheology In IgA nephropathy. R.R. Bailey, B.!. Shand, L.O.
Simpson, Department of Nephrology, Christchurch Hospital, Christ-
church, and Department of Pathology, Dunedin Hospital, Dunedin,
New Zealand. Changes in blood rheology, by causing adaptations in
renal hemodynamics, may contribute to the development of renal
disease. To determine whether abnormal blood rheology may be
involved in the pathogenesis of IgA nephropathy, 35 patients (26 males,
9 females) with the disease were studied. Rheological data from the
patients were compared to those from age and sex-matched control
subjects, and also examined to see if abnormal blood rheology corre-
lated with the clinical indices of IgA nephropathy. High and low shear
whole blood viscosity, RBC deformability and plasma viscosity were
significantly altered in patients with IgA nephropathy. A strong corre-
lation (P  0.05) was found between abnormalities in RBC rheology and
microscopic hematuna, decreased glomerular filtration rate, systolic
blood pressure and plasma protein concentration. However, the fac-
tor(s) causing impaired RBC deformability in IgA nephropathy remain
unknown, as there was no correlation between RBC filterability and
concentration of any plasma protein. Raised blood viscosity, by causing
elevated pressure gradients in the glomerulus, results in increased
amounts of immune complexes and proteins crossing the glomerular
capillary wall. In the long term the phagocytic capacity of the mesangial
cells may become overloaded, leading to functional and structural
changes in the mesangium. Improving blood rheology may provide a
means of preventing or even reversing progressive renal damage in IgA
nephropathy, the commonest fonn of glomerulonephntis in this country.
IgA rheumatoid factor in IgA nephropathy and Henoch-Schonlein
nephritis. C.L. Jones, H.R. Powell, P. Kincaid-Smith, D.M. Robe rton,
Departments of Paediatrics and Nephrology, )?oyal Children's Hospi-
tal, Melbourne, and Department of Nephrology, Royal Melbourne
Hospital, Melbourne, Australia. Recent reports have suggested that
IgA rheumatoid factors may have a significant role in the pathogenesis
of IgA nephropathy and Henoch-SchOnlein purpura (HSP). An enzyme
immuno-assay (EIA) was developed to measure serum IgA rheumatoid
factor activity towards human igG and 1gM and the murine plasmacy-
toma IgA antibody, MOPC-3 15. In a normal population IgA rheumatoid
factor activity was shown to increase with age in proportion to total
serum IgA, and the ratio of IgA rhel!matoid factor to total serum IgA
was relatively constant. The median and range of IgA rheumatoid factor
values for patients with IgA nephropathy, HSP nephritis, a control
group with diffuse mesangial proliferative glomerulonepritis (IgA -ye)
and controls without known renal disease were compared:
IgA anti-IgG IgA anti-IgM IgA anti-MOPC
HSP nephritis 16 (5-50) 23.5 (9—75) 10.5 (0—44)(N=l6)
IgA nephropathy 14(6-110) 25 (8-90) 10 (0-300)(N = 46)
DMPGN (N = 15) 14 (4-45) 21(9-100) 0 (0-40)
Control (N = 11) 13 (7-33) 21(9-150) 0(0-22)
No significant increase in IgA rheumatoid factor was demonstrable in
any group. Twelve patientswith IgA nephropathy and 12 with I-ISP
nephritis were followed over the course of a mucosal infection. No
overall association between IgA rheumatoid factor activity and disease
exacerbation was demonstrable, although some individual patients
showed a rise in IgA rheumatoid factor. Our data do not support an
important role for IgA rheumatoid factor in the pathogenesis of IgA
nephropathy or HSP nephritis.
Cellular immunoregulatlon during clinical quiescence and exacerbation
in IgA nephropathy. K.N. Lai, F.M. Lai, S.H. Chui, I'M. Chan, C.W.
Lam, Departments of Medicine, Morbid Anatomy an4 Chemical Pa-
thology, Chinese University of Hong Kong, Hong Kong. This work was
undertaken to examine the immunoregulation of T lymphocytes in
patients with IgA nephropathy. Fifty patients and thirty-seven control
subjects were studied in an infection-free interval. T lymphocyte
subpopulations were determined using OKT monoclona! antibodies
against helper (OKT4) and suppressor (OKT8) T cell subsets. The
proportions of T lymphocyte subpopulations did not differ between
patients and controls. Patients with significant renal impairment dem-
onstrated a reduced OKT4/T8 ratio (P < 0.001) due to an absolute
reduction of T helper cells (P < 0.02) and an increase of T suppressor
cells (P < 0.001). Longitudinal studjes performed in 13 patients re-
vealed consistent flndigs during clinical quiescence. However, syn-
pharyngitic macroscopic haematuria was associated with a rise in T4
positive cells and a simultaneous reduction of T8 positive cells; these
changes reverted to pre-infection values when the infection subsided.
Functional studies assessing T lymphocyte activities including in vitro
immunoglobplin synthesis by cultured peripheral blood mononuclear
cells, thymidne uptake by cultured lymphocytes and T lymphocytes
activation with expression of interleukin-2 receptors were measured in
unstimulated and mitogen stimulated cultures. No significant difference
between patients with IgA nephropathy in clinical quiescence and the
control subjects was demonstrated. Our results failedto support a shift
in the immunoregulatory T lymphocyte subpopulations during clinical
quiescence but a more profound defect in immunoregulation may
probably occur during clinical exacerbation.
Glomerular procoagulant activity is augmented in human proliferative
glomerulonephritis. PG. Tipping, J.P. Dowling, S.R. Holdsworth,
Department of Medicine, Monash University, and Department of
Tissue Pathology, Prince Henry's Hospital, Melbourne, Australia.
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Recent studies (1, 2) have implicated augmented glomerular procoagu-
lant activity (PCA) in the initiation of fibrin deposition in experimental
glomerulonephritis (GN). The mechanisms for initiation of fibrin depo-
sition and the role of glomerular PCA in human GN is unknown. Renal
tissue was obtained from two patients with rapidly progressive, cres-
centic GN, who died before receiving substantial immunosuppressive
treatment. Histological examination showed extensive glomerular
monocyte infiltration and fibrin deposition in both patients; however
Factor VIII related antigen (an index of intrinsic coagulation pathway
activation) was not present. Sonicated suspensions of isolated glomeruli
from these two patients showed markedly augmented levels of PCA
(220 and 10 mU/l03 glomeruli) compared to normal levels (0.2 0.03
mU/103 glomeruli). This PCA was functionally dependent on the
presence of coagulation Factors VII and V, independent of Factors VIII
and XII, inhibitable by concanavalin A and phospholipase C, and cell
membrane bound. These characteristics suggest this augmented gb-
merular PCA is 'Tissue Factor', and implicates extrinsic pathway
activiation in intraglomerular deposition of fibrin. Activated
monocytes, known to be a potent source of PCA and seen in lar8e
numbers within glomeruli from these patients, are a likely source of this
augmented glomerular PCA.
Quantitation of glomerular antibody deposition in human anti-GBM
disease. NW. Boyce, R.C. Atkins, S.R. Holdsworth, Departments of
Nephrology and Medicine, Prince Henry'.t Hospital, Melbourne, Aus-
tralia. A quantitative technique was developed to allow estimation of
the amount of antibody bound to antigenic targets within nephritic
human glomeruli. Methodologies applied by Groggel et alia in expen-
mental glomerubonephritis were modified to examine human renal
tissue. A patient with rapidly progressive. crescentic glomerulonephri-
tis due to antiglomerular-basement-membrane (anti-GBM) antibody
deposition was studied. Isolated nephritic glomeruli were exposed in
vitro to radiolabelled antihuman IgG antibody under incubation condi-
tions designed to achieve binding equilibrium and antigen saturation.
Paired-label radioligand binding techniques allowed quantitation of the
antihuman IgG antibody bound to isolated nephritic glomeruli. These
values were converted to units of human immunoglobulin bound to
nephritic glomeruli by construction of a series of standard curves using
isolated normal human glomeruli containing known quantities of spe-
cifically bound human anti-GBM antibody. There was 12.4 0.7 g
anti-GBM antibody globulin per iO nephritic glomeruli. By comparison
to experimental anti-GBM glomerulonephritis, this is a relatively large
quantity of glomerular bound antibody. It is likely that such levels of
antibody binding are capable of producing direct glomerular injury in
addition to recruiting and activating other inflammatory mediator sys-
tems in human glomerulonephritis. Similar techniques may be utilized
to quantitate glomerular antibody deposition in other forms of immune
renal injury.
Quantitation of intraglomerular mononuclear phagocytes in experi-
mental glomerulonephritis in the rat using specific monoclonal antibodies.
N. W. Boyce, S.R. Holdsworth, R.C. Atkins, Departments of Nephrol-
ogy and Medicine, Prince Henry's Hospital, Melbourne, Australia.
Intraglomerular mononuclear phagocytes were quantitated in normal
Sprague Dawley rats and in animals with diffuse proliferative glomeru-
lonephritis, using recently described specific monoclonal antibodies
(ED!, ED2, ED3: Dijkstra CD et al, Immunology 54:589—599, 1985) and
immunoperoxidase techniques. Results obtained with the immunoper-
oxidase technique were compared with estimates of glomerular mono-
nuclear cellularity based upon histochemistry and glomerular cell
culture. Normal animals (N = 12) had no significant glomeru!ar mono-
nuclear phagocyte population by immunoperoxidase (0.01 macrophages
per glomerular cross-section [MO/gcs]), histochemistry (+0.2 0.1
staining intensity) or glomerular cell culture (0.10 0.02 MO/glomeru-
lus [MO/glom]). Evolution of diffuse proliferative glomerulonephritis
was associated with a progressive rise in glomerular mononuclear
phagocyte infiltration using all three techniques. Irnmunoperoxidase
staining (ED!) at the time of mdximal macrophage infiltration of
glomeruli revealed 6.21 1.78 MO/gcs (N = 12) using the ED!
macrophage marker. This correlated with histochemical (+3.8 0.2
staining intensity) and glomerular cell culture (17.6 4.5 MO/glom)
estimates of the glomerular mononuclear phagocyte population. In
addition, significant numbers of intraglomerular monocytes possessed
the ED2 and ED3 macrophage differentiation antigens (0.82 0.41 and
0.24 0.15 MO/gcs, respectively). These specific monoclonal antibod-
ies thus provide a reliable: reproducible means for the quantitation of
intraglomerular mononuclear phagocytes. In addition they provide
evidence for intraglomerular macrophage differentiation in experimen-
tal glomerulonephritis in the rat.
T cell immunization after graft loss from rejection. M.G. Suranyi,
B.M. Hall, G.G. Duggin, J. Johnson, J.S. Horvath, D.J. Tiller,
Department of Renal Medicine, Royal Prince Alfred Hospital,
Camperdown, N.S.W., Australia. Patients who have previously re-
jected a graft have a higher risk of rejecting subsequent grafts, presum-
ably due to sensitization. While antibodies are readily detected, T cell
sensitization which may be more relevant is harder to detect. This study
looked for T cell sensitization following TP rejection by examining the
kinetics of three in vitro T cell functions in MLC against specific donors
compared to third party stimulation. Sensitization should cause earlier
proliferation in MLC, earlier generation of cell mediated lympholysis
(by day 4 CML > 10% specific release) and more rapid appearance of
interferon y (HGI) in MLC supernatant. Ten patients were examined
more than one month after TP rejection (8 cadaver and 2 live donors, 6
imuran and 4 CSA treated, 5 acute and 5 chronic rejection). In MLC
only one patient had secondary kinetics, 7 had 10 kinetics, I a depressed
response and I failed. D4 CML > 10% was found in 1/9 only, but D4
CML > self was found in 5/5 patients with acute rejection and 2/4
patients with chronic rejection. HGI was above the normal 10 level at 24
hours (0.7 0.82 U) in 5/7 tetted (12 6.8 U)—2/3 with acute rejection
and 3/4 with chronic rejection. Only I patient had evidence of sensiti-
zation in all 3 in vitro tests, 2 patients in 2 of 3, and 5 patients in only
I of 3. Overall 5/9 patients (56%) showed some changes in in vitro tests
that may be evidence of sensitization after graft rejection. Only if D4
CML> self was used as the marker did all patients show sensitization.
These results indicate that analysis of T cell kinetics fails to detect
sensitization in all patients likely to be sensitized.
Experimental models for gbomerular permeability. 0. Zamparo, W.D.
Comper, Department of Biochemistry, Monash University, Clayton,
Victoria, Australia. The aim of this investigation was to examine
whether passive physical processes could account for the charge
selectivity of the glomerular capillary wall, as evidenced by the ability
of macromolecular polycations to be transported at a greater rate across
the wall as compared to polyanionic material of approximately the same
molecular size. We have used a model system of a negatively charged
polysaccharide matrix to represent the polyanionic matrix within the
basement membrane of the glomerulus. We have examined the charge
selectivity of this matrix and its uncharged counterpart on the behavior
of three transport probes—namely, polycationic dextran, neutral dex-
tran and polyanionic dextran. The two physical processes envisaged to
affect charge selectivity within the gbomerular wall and studied in the
model system are: (I) the ability of macromolecules to enter the matrix
as studied by frontal gel chromatography, and (2) the rate of transport
of macromolecules within the matrix as studied in a diffusion cell. We
have established that polyanionic dextran has considerably more diffi-
culty entering a negatively charged matrix than polycationic and neutral
dextran. With respect to transport within the matrix, it was found that
polycation dextran moved faster than neutral and polyanionic dextran.
These results appear to be consistent with perfusion studies in vivo.
Caffeine aggravates mefenamic acid associated renal papillary damage.
P.J. Champion de Crespigny, P.S. Kincaid-Smith, Royal Melbourne
Hospital, Melbourne, Australia. The effect of caffeine (CAF), a fre-
quent component of compund analgesics, in combination with the
non-steroidal anti-inflammatory drug mefenamic acid (MEF) on the
renal papilla in Sprague-Dawley rats was studied. Four groups Of 20 rats
were gavage fed either control suspension (C), MEF, CAF or MEF &
CAF in combination for 5 days per week over 4 months. Four micron
thick sections were cut in a corona! plane passing through the papillary
tip and histology was graded blind. Twenty-three (59%) of 39 kidneys
from rats fed the combination of MEF & CAF developed histological
changes compared with 2 kidneys in C (5%), 14 in MEF (35%) and 5 in
CAF (13%). The MEF, CAF and C renal papillae showed only
interstitial swelling and oedema (Grade I changes) whereas in the 23
kidneys from the MEF & CAF rats the papillae showed Grade I changes
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in 2 (9%), Grade II changes (coagulative necrosis with or without
calcification) in 11(52%), Grade III changes (coagulative necrosis with
the loss of cuboidal epithelium lining the papilla) in 7 (30%) and Grade
IV changes (partial loss of necrotic papilla) in 2 (9%). Non-parametric
evaluation showed MEF & CAF vs. C; P < 0.001, MEF & CAF vs.
MEF; P < 0.005 and MEF & CAF vs. CAF; P < 0.001. These data
suggest that CAF potentiates the effect of MEF on the rat renal papilla
in non-steroidal anti-inflammatory associated renal papillary necrosis.
Coronary artery disease In renal allograft recipients survIving 10 years.
J.F. Mahony, R.J. Caterson, C.A. Pollock, A.G.R. Sheil, Departments
of Renal Medicine and Transplant Surgery, Royal North Shore Hospi-
tal, St. Leonards, N.S. W., Australia. One hundred and thirty-three
recipients of first cadaveric renal allografts between August 1967 and
December 1976 at Sydney Hospital survived at least 10 years. On
review in January 1987, 10—19 years post-transplant, 75 were alive with
a first cadaveric graft, 4 with a second cadaveric graft, 2 with a third
cadaveric graft, I with a living related graft as a second procedure, 15
were maintained on dialysis, 32 had died, and 4 were lost to follow-up.
Of the 32 deaths beyond 10 years, 12 were due to myocardial infarction,
8 to sepsis, 5 to carcinoma, 2 each to cachexia and uraemia, and I each
to cerebrovascular accident, 01 bleeding and a sudden death. Five of
the 20 recipients with non-cardiac deaths had clinical and proven
coronary artery disease. Of the 101 patients surviving 10—19 years
post-transplant, 12 have angina and 11 have myocardial infarction. Two
of the survivors and one of the non-cardiac deaths underwent success-
ful coronary artery bypass graft surgery and another has had coronary
angioplasty. With the increasing time after transplantation, coronary
artery disease exceeds sepsis as the major cause of mortality and
morbidity in renal allograft recipients. All patients with progressive
renal disorders must be advised of the risk factors for coronary artery
disease and preventative measures taken early in the course of renal
failure.
Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis—A
prospective controlled trial of intermittent vs. continuous IP administra-
tion. N,W. Boyce, C. Wood, N.M. Thomson, D. Hooke, S.R.
Holdsworth, P. Kerr, R.C. Atkins, Departments of Nephrology and
Medicine, Prince Henry's Hospital, Melbourne, Australia, The use of
intraperitoneal vancomycin therapy as initial therapy for CAPD perito-
nitis is described, with direct comparison between continuous and
intermittent antibiotic administration schedules. "Continuous" therapy
consisted of a 1 g vancomycin i.p. loading dose followed by 30 mg/liter
dialysate continuing until 5 days after macroscopic clearing of the
dialysate effluent. "Intermittent" therapy consisted of 2 doses of 30 mg
vancomycin/kg body weight administered i.p. at diagnosis and after 7
days. All patients presenting with clinical peritonitis were randomized
to either continuous or intermittent vancomycin protocols (N = 90
peritonitis episodes). Patients with peritonitis due to gram negatives,
fungi and other insensitive organisms were transferred to a more
appropriate antibiotic when identified by dialysate microscopy and
culture (N = 39). In the remainder clinical resolution of peritonitis was
seen in all patients (continuous 21/21 and intermittent 30/30—mean of
3.2 days for macroscopic clearing of dialysate effluent). Recutrence of
peritonitis within 1 month of therapy was similar in continuous and
intermittent therapy groups (4/21 vs. 3/30:P = NS), as were serum
vancomycin levels 3 and 5 days after initiating therapy. There were no
differences in observed drug side-effects. Microorganisms isolated from
dialysate cultues were comparable in both treatment groups. Thus i.p.
vancomycin therapy proved a useful initial approach to CAPD perito-
nitis. Intermittent therapy with 2 doses (I week apart) was as efficacious
as continuous antibiotic therapy. Intermittent i.p. vancomycin there-
fore provides a simple, effective mode of therapy which facilitates
outpatient management of peritonitis complicating CPD.
Evolution of the analge.sk syndrome (AS) following legislation restilcting
analgesic sales. R.S. Nanra, Department of Nephrology, Royal Newcastle
Hospital, Newcastle, N.S. W., Australia. Following introduction of
restrictive analgesic legislation in Australia in July 1979, the mean
number of new analgesic nephropathy (AN) patients seen/year fell from
65.6 (1972—79) to 36.9 (1980—86) (P <0.001). The presenting AS in 100
consecutive AN patients seen in 1972—74 (Or I) significantly differed
from the AS seen in 100 consecutive AN patients seen in 1984—86 (Gr
II). Gr II patients were older by a mean age of 11.2 years; there was a
reduction in patients presenting with severe and terminal renal failure
(of 25%), sterile pyuna (of 16%), haematuria (of 21%), malignant
hypertension (of 8% to 0), ischaemic heart disease (of 13%), gastric
ulcer (of 12% to 0), anaemia (of 27%) and cigarette abuse (of 13%); there
was an increase in misuse of nonsteroidal anti-inflammatory drugs and
uroepithelial tumor (of 6% each). No differences were noted in sex
ratio, urinary tract infections, proteinuria, renal sizes, benign hyperten-
sion, nephrocalcinosis, secondary gout, renal osteodystrophy and gas-
trointestinal hemorrhage. Conclusions: The introduction of analgesic
legislation appears to have (I) altered the AS, and (2) reduced the
incidence and severity of renal failure.
Survival following renal artery reconstruction In patients with renal
failure and atherosclerotic lesions of the renal artery. J.S. Horvath, W.
Fischer, J. May, R. Waugh, A.G.R. Sheil, A. Eyres, J. Johnson, G.G.
Duggin, B. Hall, D. Tiller, Department of Renal Medicine, Royal
Prince Alfred Hospital, Camperdown, N.S.W., Australia. Surgical
correction of renal artery stenosis/obstruction in order to preserve or
restore renal function and improve control of blood pressure was
performed on 34 patients. Their mean age was 53 9years. All patients
had a preoperative serum creatinine in excess of 200 mol/liter and the
mean for the group was 410 206 rmol/liter. Twenty-five were females
(74%); 18 of the 34 had bilateral renal artery disease. Evidence of
parenchymal renal disease was found in 26 of the 34, and 23 of the 26
had analgesic nephropathy. Thirty-one of the 34 patients had clinically
demonstrable, extra-renal vascular disease. There were 5 perioperative
deaths, 3 due to ischemic heart disease and 2 due to renal failure. Ten
of the remaining 29 patients developed ESRF from 3 to 116 months
following surgery. Five of these patients remain on dialysis or have
been transplanted, and 5 patients have died. There were a further 10
patients who died during the observation period. The actuarialsurvival
at 5 years for the 34 patients was 50%. There was no correlation
between survival and age, level of renal function or mean arterial
pressure, at the time of surgery. This group of relatively young patients
had advanced vascular disease and there was only a 42% overall
survival following surgery. Despite the absence of a control group of
patients these results suggest that the approach to the surgical manage-
nient of this particular subgroup of patients needs to be reassessed.
Correction of nephrotic hypercholesterolemia with the HMG-CoA
reductase inhibitor lovastatin. T.A. Gulper, D.R. illingworth, W.M.
Bennett, Oregon Health Sciences UnIversity, Portland, Oregon, USA.
In nephrosis there is an unexplained stimulation of the rate limiting
enzyme of eholesterogenesis, HMG-CoA reductase (Golper, J Lipid
Res 27:1044). Lovastatin (formerly called mevinolin) is a specific
inhibitor of this enzyme and is effective in treating familial hypercho-
lesterolemia (Illingworth, J Clin invest 74:1972). Eight nondiabetic
adult nephrotics (4 male, 4 female) with normal or only slightly impaired
renal function were administered placebo and lovastatin in a single
blind, dose-response study. All patients tolerated drug and placebo
without side effects or change in renal function, blood pressure, or
proteinuria. With lovastatin 7 of the 8 patients demonstrated a maxi-
mum drop in their total cholesterol by a mean (±S.D.) of 35 11%
(range 15 to 49), or 131 56 mg/dl (range 51 to 270). This was due to a
fall in LDL cholesterol. HDL cholesterol was unchanged or rose
slightly. Total triglycerides fell in the same 7 patients. The unresponsive
patient and one responder during a severe exacerbation of nephrosis
and hypercholesterolemia were the most hypoalbuminemic. Although
the hypolipemic effect of lovastatin was greatest at 80 mg/day, the
optimum dose for most responders appears to be 40 mg/day. In
conclusion, lovastatin is an effective, non-toxic hypolipemic agent in
most stable chronically nephrotic patients. These results were consist-
ent with animal data from our lab that HMG-CoA reductase is impor-
tant in the mechanism of nephrotic hypercholesteroiemia.
IgA glomerulonephritis and pregnancy. D.K. Packham, R.A. North,
K.F. Fairley, J.A. Whitworth, P. Kincaid-Smith, Department of
Nephrology, Royal Melbourne Hospital, Victoria, Australia. To deter-
mine the effect of IgA nephropathy on fetal and maternal outcome, 116
pregnancies in 70 women have been analyzed. Fetal lots was 35/118
fetuses (35%), 27 (23%) after the first trimester. Five of the six first
trimester therapeutic abortions were for medical indications. Thirty-one
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(26%) of all fetuses were premature. There was no increase in the
incidence of small for gestational age infants. Maternal renal function
was impaired during 30 (26%) pregnancies, (in only one case abnormal
renal function predated pregnancy). Hypertension developed 'de novo'
in 52 (45%) pregnancies. Of 18 cases (16%) with prior hypertension, 9
were exacerbated in pregnancy. Proteinuria was detected in 93 (80%)
pregnancies and in 74 (64%) increased significantly. Nephrotic protein-
uria developed in 10 pregnancies (9%). Post-partum impaired maternal
renal function persisted in 3 women (one patient had prior impaired
renal function). Hypertension developing in pregnancy persisted in 15
(13%) women. Increased proteinuria persisted post partum in 12 (10%).
Patients with focal proliferative lesions had more prematurity and fetal
loss (P < 0.005), and impaired maternal renal function (P < 0.005) than
those with diffuse mesangial proliferation. Pregnancy in women with
IgA nephropathy is associated with increased fetal loss and maternal
complications. In some women impaired renal function, hypertension
and increased proteinuria persist post-partum.
Screening for early detection of renal damage in children. K.F.
Jureidini, R.J. Hogg, R.A. Cockington, S. Harris, P.H. Henning,
Renal Unit, Adelaide Children's Hospital, North Adelaide, Australia.
We have developed enzyme linked immuno-absorbent assay (ELISA)
for measuring urinary B2 microglobulin (UB2M) as a screen for renal
damage in childen. The ELISA was validated by comparison with
radioimmunoassay (Pharmacia) with a correlation coefficient of 0.996 in
243 samples. Urines were tested from 2,498 children from one to 15
years attending Casualty at Adelaide Children's Hospital. Samples
were labelled and stored immediately at —20°C, and tested for UB2M in
batches of 100 by ELISA. Of these, 451 (18.1%) had UB2M levels> 350
sg/liter. Elevated UB2M/creatinine ratio was found in 236 (94%) who
were recalled, with 196 attending for review. Follow-up included full
history and examination, casenote review of the original casualty visit
and repeat urine tests. Of these, 182 had normal UB2M on review. At
original casualty visit, 181 had been reported as febrile and/or dehy-
drated. Of the 14 with raised UB2M on review, 11 had normal UB2M on
subsequent testing, were clinically normal with normal renal ultra-
sound. Of the three children with persistently high levels of UB2M, one
has significant reflux nephropathy, the second biopsy proven glomeru-
lonephritis and the third high calcium excretion but normal ultrasound.
We conclude that fever and/or dehydration cause false positive UB2M
levels, and that the validated ELISA provides a cheap, practical
method for using UB2M as a screening test for renal damage in children
without acute infection.
Thin membrane nephropathy in patients with hematuria. G.J. Perry,
C.R.P. George, M.J. Field, P.V. Collett, S. Kalowski, R.N. Wyndham,
R.C. Newland, B.P.C. Lin, K.L. Kneale, J.R. Lawrence, Concord
Hospital, N.S. W., Australia. Thin membrane nephropathy (TMN), a
characteristic attenuation of glomerular basal lamina demonstrable by
electron microscopy, is found in some patients with hematuria. Renal
biopsies usually show mild, non-specific glomenilar hypercellularity
and have no identifiable electron dense deposits or positive fluores-
cence for IgG or IgA. We have examined the renal biopsies of 68
patients with glomerular haematuria who were biopsied during 1986, 25
of whom had TMN. Sixteen TMN patients were female. The mean age
of TMN patients was 41 years (range 18 to 73); 6 had a family history of
renal disease and 4 of deafness. The history of haematuria extended
from 3 days to 30 years; 9 had experienced loin pain, 5 were hyperten-
sive, 3 proteinuric, and 4 had reduced renal function; 3 had abnormal
serum complement levels, 1 an elevated IgA level, and 3 positive
anti-nuclear factor (but with negative DNA binding); 3 had C3 deposits
in arterioles or glomeruli, and 2 had prominent interstitial foam cells. It
is concluded that TMN is common, is often associated with haematuria,
may be hereditary, may cause reduction in renal function, may mimic or
overlap various other haematuric renal diseases, and requires electron
microscopic examination of renal biopsy material for recognition.
SP4O,40—A new complement protein found in glomerular immune
deposits. B.F. Murphy, A.J.F. d'Apice, Royal Melbourne Hospital and
St. Vincent's Hospital, Melbourne, Australia. We have isolated and
characterized a new glycoprotein, SP4O,40, which is present in moder-
ate concentration (35—105 g/ml) in normal human serum (and plasma).
The protein was initially identified during studies of the composition of
immune deposits in kidneys with glomerulonephntis. SP4O,40 is a
component of the SC5b-9 complement complex, but is not present in
MC5b-9 complexes extracted from antibody/complement lysed eryth-
rocytes. SP4O,40 is distinct from S protein and the complement com-
ponents C5,6,7,8 and 9, the known components of SC5b-9 complex. It
is an inter alpha globulin of 8OkD and consists of two 4OkD disulphide
linked chains. The p1 of the heterodimer and the separated chains are
heterodisperse (4.5—5.2). The N-terminal amino acid sequences (25
amino acids) of each chain are unrelated to each other and bear no
homology to known protein sequences of man or animals. Immunohis-
tologic studies of 20 renal biopsies of patients with a variety of forms of
glomerulonephritis show deposition of SP4O,40 in a pattern identical to
that of the terminal complement components which were examined on
sequential sections. The results suggest that SP4O,40 is a component of
the complement system analogous to, but distinct from, S protein and is
a component of the immune deposits of glomerulonephritis.
Serum polymeric IgA in mesangial IgA nephropathy. C. Jones, N.
Mermeistein, H. Powell, P. Kincaid-Smith, D. Roberton, Departments
of Paediatrics and Nephrology, Royal Children's Hospital, Melbourne,
and Department of Nephrology, Royal Melbourne Hospital, Mel-
bourne, Australia. The origin of the polymeric IgA (pIgA) present in the
mesangium of patients with IgA nephropathy is unknown. A mucosal
site of origin is possible. An enzyme immunoassay to estimate serum
concentrations of pIgA and pIgA subclasses was developed. The assay
utilized secretory component to bind pigA. Serum pentameric 1gM
caused competitive inhibition of pIgA binding to secretory component.
Quantitation of pIgA in a serum sample involved reading the absorb-
ance value of the sample against the absorbance values of that standard
reference serum containing approximately the same 1gM concentration
as was present in the sample. The median and range of serum pIgA











IgA nephropathy 3.0 500 450 200(N = 39) 1.1—4.6 (160—1000) (140—1100) (30—170)
Controls 1.4 245 280 170(N = 39) 0.8—4.5 (90—900) (90—900) (10—510)
Wilcoxon RST P = 0.001 0.003 0.013 0.255
The ratio of pIgA and pIgA subclasses to total IgA was not significantly
different in the IgA nephropathy group. Twenty-three patients and 15
controls followed over the course of a respiratory tract infection had a
rise in pIgA (P = 0.01 and P = 0.05, respectively) and the patients with
IgA nephropathy also had a rise in pIgAi (P = 0.025) and in the ratio of
pIgA to total IgA (P = 0.01) during the first week of infection. These
data indicate that mucosal events are associated with changes in serum
pIgA concentrations.
Renal tubule collagen-gel tissue culture—A new in vitro method to
study tubulointerstitial disease. C.J. Roe, R. Whitehead, J.P. Dowling,
R.G. Walker, P.S. Kincaid-Smith, Royal Melbourne Hospital, Ludwig
Institute, Prince Henry's Hospital, Melbourne, Australia. Methodolog-
ical considerations have previously limited the use of in vitro models to
study renal tubular disease pathogenesis. The following in vitro model
permits both tubule cell viability and retention of three-dimensional
morphology. Microdissected rabbit renal tubule segments were sus-
pended in collagen gel bathed in RPM! 1640 medium containing 10%
FCS, I sg/ml hydrocortisone, 0.6 tg/ml insulin, 105M thioglycerol, 50
IU penicillin and 50 IU streptomycin and incubated at 37°C in 5% CO2
in air for 14 days. Epidermal growth factor (EGF) was added to a final
concentration of 10 ng/ml. Cultures were assessed daily by phase
contrast microscopy and by light microscopy at completion. Distal, but
not proximal nephron epithelia remained viable for 14 days and three-
dimensional morphology remain intact. Tubule lumens contained epi-
thelial cells in varying stages of necrosis, probable Tamm-Horsfall
glycoprotein (THG) and glycogen. When THG was present the adjacent
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epithelial cells showed intracytoplasmic vacuolar changes. This model
overcomes previous limitations. Both cell viability and three-dimen-
sional morphology persist in vitro for 14 days. This model therefore
makes possible an analysis of the morphology, biochemistry and
hormonal responsiveness following addition of a cystogen or other
tubulointerstitial disease-producing agent.
The structure of the normal human glomerular basement membrane
and changes in "benign" hematuria as determined with the Immunogold
technique. P.S. Smith, I. Aarons, J.C. Fanning, Renal Laboratory,
Department of Tissue Pathology, Institute of Medical & Veterinary
Science, Frome Road, Adelaide, Australia. The immunogold technique
is used for the ultrastructural localization of Type IV collagen and
laminin in the human glomerular basement membrane ((iBM). The
location of Goodpasture's antigen is also determined with this tech-
nique using serum from a patient with Goodpasture's syndrome as the
primary antibody. The structure of the GBM as proposed by other
workers (Martinez-Hernandez et al 1983) depicts a Type IV collagen
lattice throughout the entire thickness of the membrane with laminin
and heparan sulphate attached predominantly in the laminae rarae. The
present study indicates this propoal to be incorrect. Type IV collagen is
located in the subendothelial third of the membrane and is in direct
communication with the mesangial matrix. Laminin appears to be
uniformly distributed throughut the GBM as does Goodpasture's anti-
gen. A new (iBM structure is proposed based on the locations, sizes
and properties of these molecules. Changes to this structure are
assessed in the attenuated GBMs in patients with "benign" hematuria.
In this condition the subendothelial Type IV collagen lattice is retained,
but the external (epitheial) half of the membrane appears to be greatly
reduced, Concomitant with this is a reduction in the localization of
laminin and Goodpasture's antigen. The application of the immunogold
technique provides new insights into the structure of the normal human
GBM. It also provides the first demonstration of changes occurring in
the attenuated membranes of "benign" hematuria, It is expected that
further investigations along these lines will continue to supply new
information about this and other diseases.
Modification of renal and tissue cation transport by CCK-8. K.A.
Duggan, G. Hams, G.J. Macdonald, The Prince Henry Hospital,
Sydney, Australia. Reports that gastric sodium loads cause a greater
natriuresis than those administered intravenously suggest a gastric or
portal sodium monitor exists which may release a humoral natriuretic
factor. To determine if CCK-8 could be a candidate for this gut-derived
natriuretic factor, we compared the natriuretic responses to CCK-8
infused intravenously and intrarenally in six conscious male rabbits.
The route of administration was randomized and a stepped dose
protocol was followed with 30 mm infusion periods for each dose.
Blood pressure was monitored and urine collected throughout each
dose. Blood was sampled at the end of each infusion period to
determine renal plasma flow (1251 hippuran clearance), glomerular
filtration rate (endogenous creatinine clearance) and fractional electro-
lyte excretions. Responses at each dose were analyzed for change from
control by Student's t-test and for linear trend with log dose of CCK-8
infused. On renal infusion, CCK-8 produced significant log dose depen-
dent decreases in the fractional excretions of calcium (t = —2.3865, P <
0.05) and magnesium (t = —2.7639, P < 0.025) and in both a log dose
dependent increase in fractional sodium excretion (t = 2.9239, P <
0.025). The significant decreases in the fractional excretions of calcium
and magnesium were accompanied by log dose dependent falls in their
plasma levels (calcium t —4.0497, P < 0.005) and magnesium (t =
—5.0020, P < 0.005), indicating a movement of calcium and magnesium
to extravascular sites. Studies of tissue calcium and magnesium levels
in response to CCK-8 infusion showed that calcium accumulated in
kidney and skeletal muscle. We conclude that CCK-8 has direct renal
natriuretic effects at the tubular level and could be the gut-derived
natriuretic factor. In addition to its effects on sodium excretion, CCK-8
causes retention of calcium and magnesium with movement of these
ions to extravascular sites.
Localization and characterization of renal calcitonin receptors by in
vitro autoradiography. P.M. Sexton, W.R. Adam, f.M. Moseley, T.J.
Martin, F.A.O. Mendelsohn, University Department of Medicine,
Austin and Repatriation General Hospitals, Heidelberg, Victoria, and
Renal Unit, Repatriation General Hospital, Heidelberg, Victoria, Aus-
tralia. In the kidney, calcitonin (CT) has been shown to influence fluid
and electrolyte handling as well as the metabolism of vitamin D.
Whether these actions are mediated by local receptor interaction or not
remains unclear. To help answer this question, CT binding sites in the
rat kidney have been localized and characterized by in vitro autoradi-
ography. Briefly, 20 m kidney sections were incubated in 50 mri Tris
HC1, 100 mrs NaCl, containing 0.2% BSA, 0.05% bacitracin and
'251-salmon CT (82 pM) with or without competing analogs. The sections
were then washed, dried and exposed to x-ray film. Autoradiographs
were analysed by computerised scanning densitometry. Calcitonin
receptor binding sites were identified in renal cortex and medulla. Light
microscopic localization of these receptors revealed binding over
medullary and cortical thick ascending limb (of the loop of Henle) and
in distal convoluted tubule. A number of CT-receptor positive cells in
the inner medulla were also identified. Characterization of the binding
sites demonstrated a single class of high affinity sites in both the
(medulla and cortex with affinity constants of 0.74 0.09 x l09M and
0.32 0.05x lO9M'' respectively and receptor concentrations of 205
45 fmol/mg and 453 54 fmol/mg protein, respectively.) Competition of
'251-salmon CT binding by a wide range of CT analogs revealed a close
correspondence betwen the reported biological potencies of the analogs
and their activity in this radioligand binding system. The localization of
binding sites within the nephron corresponds to the reported localiza-
tion of CT-sensitive adenylate cyclase and suggests that the receptor
mediated actions of CT in the kidney utilize cyclic AMP as a second
messenger. In addition the morphological localization of specific CT
receptor binding helps the delineation of direct actions of this hormone
from those which are indirect.
Assessment of T cell crossmatch pretransplant. M.G. Suranyi, B.M.
Hall, G.G. Duggin, f. Johnson, J.S. Horvath, D.J. Tiller, Department
of Renal Medicine, Royal Prince Alfred Hospital, Camperdown,
N.S. W., Australia. Sensitization to HLA antigens is considered to be a
major risk factor in transplantation (TP). This study examines prospec-
tively the incidence and significance of T cell presensitization detected
before cadaver TP. The kinetics of three in vitro tests of T cell function
have been examined in an attempt to detect changes indicative of
sensitization. These were accelerated MLC kinetics, significant (>10%)
specific cell mediated lympholysis (CML) at day 4 of MLC and high
gamma interferon (HGI) production at 24 hours. Thirty-one patients








HG?20 High 10 Normal Low
ALL 31 6 3 10 4 8 5
Previous TP 8 1 1 2 1 3 0
Cytotoxic 5 0 1 2 0 2 0
Ab's
> 25%
Previous preg- 7 2 0 1 1 3 0
nancy
Acute
rejection 16 4 2 4 3 4 3
Nephrectomy 4 2 0 1 0 0 0
A total of 13/31 patients demonstrated some form of 2° kinetics;
however these tests fail to identify patients with pre-existing risk of
sensitization or those going on to acute rejection or nephrectomy. The
current in vitro assays to detect T cell sensitization are insensitive
because they rely on in vitro tissue culture techniques that involve
many uncontrollable variables. Whether this contributed to the lack of
correlation with outcome or whether other factors such as responder
status of the recipient and the efficiency of immunosuppression are
important is unknown.
Long-term dietary treatment supplemented with essential amino acids
and keto acids in chronic renal failure. R. Schmicker, P.T. Frohling, I.
Handschuck, I. Kaschube, K. Lindenau, K. Vetter, Department of
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Internal Medicine, W. Pieck University, Rostock, GDR. The aim of this
study was to investigate the effect of a low protein diet supplemented
with essential amino acids (EAA) or their keto analogues (KA) on
uremic metabolism, rehabilitation status and progression in chronic
renal failure. A group of 119 patients with advanced renal failure (initial
serum creatinine level 733 186 mol/1iter) was included in this
long-term study. The protein intake amounted to 0.4 k/kg body
weight/day, the phosphorus intake 0.4—0.6 g/day and the energy supply
120—150 kJ/kg body weight/day. In 51 patients there was a substitution
with EAA and in 68 patients with their KA. The mean duration of
treatment was 19 months (6—64 months). During this time, the serum
creatinine level increased from 733 186 to 1220 256 mol/liter,
whereas the urea nitrogen levels remained relatively constant at be-
tween 26 and 30 mmol/liter. There were no signs of protein malnutrition
(nitrogen balance, serum transferrin and serum protein were normal).
The hemoglobin concentration remained at >5 mmol/Iiter with creati-
nine levels of 1220 256 imo1/liter. During the substitution with KA,
there was a significantly greater decrease in serum phosphate (P < 0.01)
and PTH (P < 0.1) as compared with the patients given EAA. Of the 119
patients, 25 patients (21%) were able to perform fulltime-professional
work, and 79 patients (66.4%) part-time work. The rate of progression
was delayed in patients treated with the supplemented diet in compar-
ison to patients on a moderate protein restricted diet (0.6 glkg/day). The
time interval between serum creatinine of 500 and one of 900 rmoIIliter
was 19 and 11 months, respectively (P < 0.01). It can be concluded that
a low protein diet supplemented with EAA or KA can improve the
uremic metabolism and rehabilitation status, and delay the progression
of chronic renal failure.
Patients with declining renal function treated with long-term low
protein diet. M.C.G. Holmes, Queen Victoria Medical Centre, Mel-
bourne, Victoria, Australia. The purpose of this study was, first, to
assess long-term compliance with such diets and, second, to assess
their effects on renal function. Eleven patients had deteriorating renal
function as measured by at least 3 serial creatinine measurements over
periods of 6 months to 4 years prior to going on the diets. Five patients
who were placed on 0.5 g/kg protein diet had a mean creatinine of 260
micrograms per ml, and 6 patients who were placed on 0.3 g/kg protein
diet had a mean creatinine of 336 micrograms per ml, at commence-
ment. Patients were counselled and assessed by a dietitian at 6-weekly
intervals for a mean period of 1.5 years. Nine of the patients were
assessed as compliant. Five of these showed complete arrest of decline
in renal function and the remaining 4 showed markedly reduced rates of
decline. The mean rate of decline expressed as the change in the
reciprocal of the creatinine per year in all diet-compliant patients was
1.4 pre-diet and 0.15 post-diet. Mean DTPA clearance was 30 ml per
minute pre-diet and 27 ml per minute post-diet. Mean plasma albumin
was 42.5 pre-diet and 42.1 post-diet. Two patients who were assessed as
non-compliant did not show any change in rate of decline of function. It
is concluded that, with appropriate supervision by dietitians, most
patients are compliant with very low protein diets and that these diets
either arrest the decline or markedly reduce the rate of decline of renal
function in such patients.
Disturbances of amino acid (AA) and keto acid (KA) metabolism in
early renal failure. K. Vetter, P. T. Frohling, K. Langer, M. Brandl, H.
Sperschneider, K. Ljndenau, W. Feki, Academy of Science of the GDR,
Central Institute of Nutrition, Potsdam-Rehbrucke, Research Clinic of
Nutrition. The total amino acid pattern (including tryptophan and
methylhistidine) and branched chain keto acids were determined in 67
patients with early renal failure (creatinine 4.0 mg/dl). Ten of them were
treated for 12 months with a low protein diet, to prevent the progression
of renal failure. Twelve patients with advanced renal failure served as a
control group. Surprisingly the keto acid levels were diminished in early
renal failure in spite of normal levels of the corresponding AA.
Phenylalanine and 3-methylhistidine were increased and threonine was
reduced in early renal failure. In advanced renal failure patients
revealed significantly decreased levels of branched chain AA and KA,
if the low protein diet was not substituted with keto acids. Protein
restriction in early renal failure leads to a normalization of keto acids
but not to a decrease of valine, tyrosine and lysine. Phenylalanine and
methyihistidine were not influenced by the low protein diet. These data
indicate that protein restriction in early renal failure is not harmless
when applied over a long period. Substitution of some amino acids will
be necessary for a long-term treatment to prevent the progression of
renal failure.
Hair and serum aluminium (Al) levels in children with chronic renal
failure (CRF). D. Schell, A. Rosenberg, R. Weintraub, M. Florence,
Department of Nephrology, Prince of Wales Children's Hospital,
Randwick, and CSIRO, Lucas Heights, N.S. W., Australia. Aluminium
intoxication is associated with progressive encephalopathy and vitamin
D resistant osteomalacia in long-term dialysis patients and in non-
dialyzed children receiving aluminium hydroxide gels for phosphate
binding. Plasma Al levels do not correlate well with toxicity and do not
reflect total body stores of Al. Therefore hair Al content was investi-
gated. Occipital hair was collected and extensively washed to remove
contaminants. Hair Al was measured by neutron activation analysis.
Plasma Al concentration was determined by electrothermal atomic
absorption spectroscopy. Five groups of patients were studied:
I. (N = 7) Children with normal renal function and glomerular
filtration rate (GFR) > 85 mI/mm/I .73 m2; no Al
2. (N 8) Mild CRF (GFR> 30 ml/min/1.73 m2); no Al
3. (N = 5) Severe CRF (GFR < 30 ml/min/l.73 m2); no Al
4. (N = 8) Severe CRF; oral Al
5. (N = 6) Continuous ambulatory peritoneal dialysis (CAPD) pa-
tients; oral Al
Group 1 2
Plasma Al <1.0 <1.0
Hair Al 5.1 0.7 10.6 2.0
3 4 5 Units
<1.0 1.9 0.6 2.2 0.4 mol/liter
5.2 0.8 13.3 1.8 4.7 0.3 parts/ml
Plasma Al levels in groups 1, 2 and 3 did not differ from the normal
population, defined in this laboratory as <1.0 mol/liter. Plasma levels
were elevated in those groups receiving oral Al (groups 4 & 5). Hair Al
was significantly elevated in group 4 compared to groups 1, 3 and 5 (P
<0.01). The low hair Al levels in group 5 in the presence of elevated
plasma Al suggest that CAPD is effective in removing Al from hair. In
group 4 hair did not correlate with retrospective estimation of cumula-
tive A! intake expressed per m2. One patient in group 2 with very high
hair Al level contributed significantly to the elevated mean in this group.
The reasons for this high level are unexplained. Hair Al is elevated in
non-dialyzed children with CRF taking oral Al and may reflect tissue
burden. In these patients hair Al may be a better indicator of toxicity
than plasma levels. To investigate this further, hair Al levels should be
compared with total bone Al and Al uptake at the bone mineralization
front.
CrEDTA/TcMDP ratio—A new radionuclide method for assessment of
renal osteodystrophy. S.M. Gruenewald, R.M. Fawdry, D.C. Farlow,
J.H. Stewart, Westmead Hospital, Wesimead, N.S.W., Australia.
Bone metabolism is difficult to quantitate and can only be assessed by
indirect techniques or examination of a small biopsy sample. Dialysis
patients were studied with a new radionuclide method of assessing renal
osteodystrophy. The technique involves simultaneous injection of an
accurately measured mixture of 5ICrEDTA and mTcMDP. Both
substances are cleared from plasma by glomerular filtration and diffu-
sion into the extravascular space while only MDP is taken up by bone.
The CrEDTA/TcMDP ratio was compared in 57 patients (44 HD and 13
PD) against serum calcium, phosphate, alkaline phosphatase (SAP) and
parathyroid hormone as well as bone scan images, forearm bone density
and radiology. Forty-seven of these patients (39 HD and 8 PD) had a
second study performed approximately one year later to assess change.
In the initial study 93% (53/57) had abnormal isotope ratios with average
2.4 0.7 (normal range 0.95 0.25), 75% (43/57) had abnormal bone
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scan images, 35% (19/54) had radiologic osteodystrophy and 30%
(17/57) had raised SAP. In patients with normal SAP, the avenge ratio
was 2.1 0.5 while if the SAP was abnormal, the average ratio was 3.0
0.9 (P C 0.001). A poor correlation was shown between the ratio and
bone density. In the progress study, there was agreement about the
direction of change in the result of the SAP and CrEDTA/TcMDP ratio
in 81% (38/47) but in 39% of these (15/38) the SAP remained within the
normal range. The CrEDTA/TcMDP ratio is proposed as a simple
method of quantitating bone uptake of MDP for assessment and
follow-up of renal osteodystrophy.
Dialysis and transplantation in end-stage renal failure due to lupus
nephritis—The Australian and New Zealand experience. CA. Pollock,
L.S. Ibels, Department of Renal Medicine, Royal North Shore Hospi-
tal, St. Leonards, N.S.W., Australia. Controversy exists in the litera-
ture as to the prognosis of patients with end-stage lupus nephritis on
renal replacement programs, We report on the prevalence and outcome
of those patients treated with dialysis and transplantation in Australia
and New Zealand. 5726 patients entered end-stage renal failure (ESRF)
programs between 1977 and 1985. Glomerulonephritis (GM) was the
primary cause of renal failure in 1999 patients (35%). Sixty-three
patients (47F, l6M) had renal failure due to SLE, a prevalence as a
cause of failure of 1.1%. These patients were significantly younger and
had a significantly higher proportion of females compared with other
forms of UN. Forty-four patients were treated with dialysis alone and
19 patients were treated with dialysis and transplantation. Integrated
patient survival was 88% at one year and 71% at 5 years. Survival of
patients treated with dialysis alone was 85% at one year and 65% at 5
years. Twenty-two transplants were performed on 19 patients (14F,
SM). Patient survival was 95% at one year and 83% at 5 years. Graft
survival was 75% at one year and 70% at 5 years. One graft failed due
to surgical complications. All other grafts failed with acute rejection.
Fifteen of the 63 patients died with infection being the major cause of
death. We conclude that lupus nephritis is a relatively rare cause of
renal failure in Australia and New Zealand, and a favorable prognosis,
comparable to that of patients with ESRF due to other forms of GN and
of all forms of ESRF on dialysis and transplantation, can be expected.
Sequential studies on atrial natriuretic peptide in pregnant and non-
pregnant baboons (Papio hamadryas). A.F. Phippard, G.P. Hodsman,
J.S. Horvath, C.I. Johnston, G.G. Duggin, D.J. Tiller, Department of
Renal Medicine, Royal Prince Alfred Hospital, Sydney, and Depart-
ment of Medictne, University of Melbourne, Austin Hospital,
Heidelberg, Victoria, Australia. The object of this study was to
determiae sequential changes in arterial plasma concentration of atrial
natriuretic peptide (AMP) which accompany pregnancy in the non-
human primate. We have previously shown that cardiac filling pressure
decreases in early primate pregnancy, then returns to normal non-
pregnant values during mid-pregnancy as circulating blood volume
increases. Arterial blood samples were collected with EDTA during
these haemodynamic studies, centrifuged at 4°C and the separated
plasma stored at —80°C. AMP levels were measured by radio-immuno-
assay. Measurements of ANP were obtained in six pregnancies at 4, 6,
8, 12, 16, 20 and 24 weeks gestation and the same animals served as
non-pregnant controls, The results showed a decrease in arterial plasma
AMP concentration during eariy pregnancy, which returned to non-
pregnant levels in mid-pregnancy and was then elevated closer to term.
Gestation Non-
weeks preg. 4 6 8 12 16 20 24
Mean AMP 30.2 13.2 15.5 17.0 28.0 73.3 103.7 168.8
pg/mI,
N= 6
5EM ±2.8 ±1.0 ±1.7 ±2.2 ±1.6 ±12.2 ±24.3 ±34.1
consistent with progressive alterations in haemodynamics and blood
volume through primate pregnancy which we have previously de-
scribed.
AtrIal natrluretic factor: Plasma concentrations in normal pregnancy.
B. Jackson, G.P. Hodsman, P.S. Allen, C.!. Johnston, Melbourne
University, Department of Medicine, Austin Hospital, Heidelberg,
Victoria, Australia. Atrial natriuretic factor (AMF) is a potent vasoac-
tive peptide which has significant effects on vascular smooth muscle
and kidney function. Plasma AMP concentration is regulated by
changes in atrial pressure, and is known to be elevated in conditions of
increased intravascular volume. We have measured plasma ANF
concentration using a sensitive radioimmunoassay in a cross-sectional
study of normal non-pregnant and pregnant women. In six non-pregnant
women plasma ANF (pg/mI, mean ± SCM) was 8.3 ± 0.9 immediately
before menstruation and 10.6 ± 1.9 one week after menstruation (NS).
Plasma ANF was measured in 67 normotensive women whose pregnan-
cies were judged to be uncomplicated at that time. Plasma AMP was
12.7 ± l.4(N = 13) in the first trimester, 19.0 ± 2.3 (N = 11, P <0.01)
in the second trimester and 22.3 ± 1.4 (N = 43, P < 0.01) in the third
trimester. There was a weak but significant correlation between gesta-
tion (weeks) and plasma AMF over the entire period of gestation (r =
0.35, P < 0.003). Four pregnancies were subsequently complicated by
hypertension without proteinuria or oedema. Plasma AMP in these
women (third trimester) was 17.7 ± 3.3, similar to that in pregnancies
without subsequent complication. Two pregnancies were subsequently
complicated by hypertension, proteinuria and oedema. Plasma ANF in
these women (third trimester) was 25.1 and 44.8 pg/mI. In normal
pregnancy the 30% increase in intravascular volume is not associated
with large changes in atrial pressure. This is a possible explanation for
the relatively small absolute increase in AMP observed, despite the
major increase in intravascular volume, The atrial natriuretic factor
may however contribute to the regulation of vasomotor tone and renal
function in pregnancy.
Hormones affecting calcium excretion. K.A. Duggan, G.J. Macdon-
ald, The Prince Henry Hospital, Sydney, Australia. At present the
maintenance of calcium balance is thought to reflect the interaction of
parathyroid hormone (PTH), calcitonin and vitamin D, parathyroid
hormone and vitamin D controlling absorption and calcitonin and P'FH
controlling excretion. However, some other peptide hormones such as
gastrin and vasoactive intestinal peptide (VIP) have been shown to be
released in response to intraluminal calcium and they or other gut
peptides may have a role in calcium homeostasis. To determine the
effects of gut peptides on calcium excretion, renal artery infusion
studies of 14 peptides were performed in conscious male New Zealand
white rabbits. The order of peptide administration was randomized and
each dose was infused for 30 mins during which blood pressure was
monitored and urine collected. Blood was sampled at the end of each
infusion period to determine renal plasma flow (1251 hippuran clear-
ance), glomerular filtration rate (endogenous creatinine clearance) and
fractional calcium excretion (FEca). Responses were assessed for
change from control by Student's t-test and for linear trend with log
dose of peptide infused. Of 14 peptides studied, only four affected renal
calcium excretion as indicated by significant changes in the fractional
excretion of calcium compared with control infusion. Pentagastrin
decreased FEca(%) from 32.43 ± 6.73 to 11.45 ± 2.94 at an infused dose
of lO3pmol kr'min' (P C 0.05) while gastric inhibitory peptide (GIP)
decreased FEca from 24.99 ± 7.21 to 12.71 ± 2.55 at an infused dose of
l0'pmol kg'min (P C 0.05). Peptide YY (PYY) had the same
effective dose as GIP, decreasing FEca from 36.80 ± 2.90 to 22.70 ±
4.26 (P C 0.01) while pancreatic polypeptide caused a significant
decrease at lo4osmol kg'min' from 19.53 ± 4.11 to 5.96 ± 1.31 (P
<0.025). Although the effective dose for gastrin represents a pharma-
cological effect, the doses of GIP, PYY and pancreatic polypeptide fell
within physiological ranges and these peptides may be involved in the
control of calcium excretion.
This study may explain conflicting observations to date that levels of
ANP are unchanged or increased in pregnancy. The sequential mea-
surements throughout pregnancy, as opposed to previous cross-sec-
tional studies, indicate a progression of changes which include a fall in
early pregnancy that has not been reported in the past. The changes are
Control mechanisms for magnesium excretion. K.A. Duggan, G.J.
Macdonald, The Prince Henry Hospital, Sydney, Australia. Urinary
magnesium excretion reflects a balance between the filtered load and
tubular reabsorption. Although the bulk of reabsorption occurs in the
loop of Henle, the mechanism which controls it has not been elucidated.
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However, since the excretion rate is responsive to dietary magnesium
control, gut hormones may be part of the mechanism which links
dietary intake and the rate of excretion. To investigate which of the gut
peptides might be involved in the control of magnesium excretion, renal
artery infusion studies of 14 peptides were performed in conscious male
New Zealand white rabbits. The order of peptide infusion was random-
ized and a stepped dose protocol was followed with 30 mm infusion
periods for each dose, during which blood pressure was monitored and
urine collected. Blood was sampled at the end of each infusion period to
detennine renal plasma flow (1251 hippuran clearance), glomerular
filtration rate (endogenous creatinine clearance) and fractional magne-
sium excretion (FEMg). Responses at each dose were assessed for
change from control by Student's t-test and for linear trend with log
dose of peptide infused, Of 14 peptides studied, one (bombesin)
increased magnesium excretion and six (somatostatin, secretin, peptide
YY, pancreatic polypeptide, cholecystokinin-8 and glucagon) de-
creased it. FEMg (%) increased from 21.07 1.76 to 28.50 3.46 at an
infused dose of 100 pmol bombesin kgmin' (P < 0.05). Secretin
infusion caused a decrease from 40.82 4.93 to 23.59 2.35 at 10—2
units kg'min' (P < 0.05); glucagon at a dose of lO5pmol kgmin'
from 38.46 2.61 to 23.44 2.00 (P < 0.025) and somatostatin at
lO2pmol kg'min' from 27.39 3.03 to 17.74 1.68 (P < 0.05). The
structurally related peptides, pancreatic polypeptide and peptide YY
decreased FEMS from 38.38 3.8 to 24.00 4.30 (P < 0.025, lO4pmol
kgmmn') and from 43.66 4.23 to 31.16 4.81 (P < 0.05, lO4pmol
kg'min'), respectively. CCK-8 will be discussed separately. Al-
though the effective dose for bombesin represents a pharmacological
effect, the doses for the other peptides fall in physiological ranges so
that they may be involved in the control of magnesium excretion,
Factors influencing urinary magnesium excretion during diuresis in
rats. J.S. Chrisp, J.R. Lawrence, M.J. Field, Department of Medicine,
University of Sydney, Concord Hospital, N.S. W., Australia. To ex-
plore the variables which determine the extent of magnesium wasting
during acute diuresis, we conducted clearance experiments in
anaesthetized intact Wistar rats (N = 5—6 per group) infused with
Ringer solution. To establish whether the effect on Mg excretion was
dependent on the mechanism of diuretic action, vigorous diuresis was
induced by four different treatments. Frusemide (F) caused the greatest
increase in fractional excretion of magnesium (FEMg) for a given rise in
urinary flow rate, as assessed by regression analysis. The slope (b) of
this relationship was 0,41% per il/min/100 g, with an estimated stan-
dard error [sE(b)] of 0.04. Saline volume expansion (S) also stimulated
Mg excretion, but was less effective than F lb = 0.22, sE(b) = 0.03].
Volume expansion using isotonic sodium bicarbonate (B) had no effect
on FEMg, even at very high flow rates lb = 0.02, sE(b) = 0.031.
Unexpectedly, osmotic diuresis induced by urea (U) caused a small but
significant depression in FEM5 [b = —0.07, sE(b) = 0.05]. We conclude:
(1) During acute diuresis in rats, Mg excretion is influenced by factors
other than the rate of diuresis itself; (2) interference with loop of Henle
function, such as by F, produces the most marked stimulation of FEMg;
(3) inhibition of proximal tubular reabsorption, such as during S, is less
potent in this regard; (4) urinary alkalinization (with B) opposes the
Mg-losing effect of diuresis; and (5) urea promotes tubular Mg reab-
sorption, possibly by passively concentrating the ion in the loop of
Henle.
Vasopressin and blood changes during dehydration and rehydration.
J.R. Blair-West, A.P. Gibson, R.L. Woods, A.H. Brook, Howard
Florey Institute of Experimental Physiology and Medicine, University
of Melbourne, and Baker Medical Research Institute, Alfred Hospital,
Melbourne, Australia. Water restriction of sheep for 9 days increased
plasma vasopressin concentration (pAVP) but did not increase haema-
tocrit (Ht). Rehydration by drinking to satiation caused a rapid fall in
pAVP before plasma osmolality (pOsm) fell. Experiments were per-
formed to define the relations between pAVP, pOsm and haematolog-
ical changes during water restriction and rehydration. Sheep were
restricted to 500 ml of water/day for 9 days. Blood samples were taken
and then water was given at 0930 hr each day. On day 9 the sheep were
given: free access to water (N = 4), 1.0 liter of water (N = 4), or a bin
of water but denied access to it (N = 4). Effects were evaluated by
paired t-test (P < 0.05 *, P < 0.01 **), Over 9 days of water restriction
the weight loss was 3.9—4.5 kg, pAVP rose gradually from 3.2 0.6 to
12.7 1.8 pg/mI, and urine flow fell to —200 mi/day. The pOsm rose
from 292 2 to 309 2 mOsmol/kg (**) on day 5 and fell to 303 2
mOsmol/kg (*) on day 9. Similar early peaks occurred in plasma
proteins (6.4 0.2, 7.1 0.2 (*) and 6.8 0.2 g%), Ht(29.4 1.3, 31.0
1.2 (*) and 29.3 1.2 (*) %), blood Hb and RBC count. Mean
corpuscular volume fell from 40.9 0.9 to 38.6 0.8 3(**) on day 4
and was 39.0 1.1 on day 9, consistent with pOsm changes. The pAVP
fell to 5.8 0.3 pg/mI (*) 15 mm after drinking to satiation (3.5—4.5 1)
and continued to fall, fell to 8.4 1.0 pg/mi (*) 15 mm after drinking 1.0
liter and then rose, and did not fall after water presentation only. The
pOsm did not fall until 30 mm after satiation and did not fall in the other
two experiments. However, Ht, blood Hb, RBC count and plasma
proteins all fell significantly (*) in 30 mm in all experiments. Hemocon-
centration occurred only during the early phase of prolonged dehydra-
tion and then solutes and RBCs were subtracted from the blood. The
progressive rise in pAVP was not interrupted. The rapid fall in pAVP,
after drinking even small volumes of water, was not due to reduction of
pOsm nor to the isosmotic dilution of blood by the shift of a lymph-like
fluid into the circulation. The mechanisms of these adaptations in blood
composition and the rapid fall in pAVP after drinking remain to be
explained.
Micropuncture comparison of nephron function during acute and
chronic ADH excess. K.T.F. Seow, J.R. Lawrence, M.J. Field, Depart-
ment of Medicine, University of Sydney, Concord Hospital, N.S. W.,
Australia. Antidiuretic hormone (ADH) may have long-term "trophic"
effects on the structure and function of the loop of Henle. To explore
the differences in nephron function between acute and chronic admin-
istration of large doses of ADH, we performed simultaneous clearance
and free-flow micropuncture experiments on normal Wistar rats during
hypotonic saline infusion. Control rats received no ADH, while acute
animals received ADH at 50 mU/hr during the study, and chronic rats
received ADH at the same rate continuously for 10—12 days before
study by subcutaneous osmotic minipump. Key clearance data were as









Control 103 4 0.9 0.1 0.1 0.05 270 60 24 7
Acute 134 4 1.4 0.1 1.1 0.2 1590 100 6 1
Chronic 115 4 1.3 0.1 0.02 0.01 2280 100 2.1 0.1
Micropuncture data indicated better water reabsorption in superficial
loops in chronic than acute rats (early distal TF/P inulin ratio 4.6 0.2
vs. 3.9 0.2, P < 0.05), while late distal segments responded equally to
ADH in both groups. Water reabsorption in the collecting ducts was
also greater in the chronic group. We conclude: (1) Chronic exposure to
excess ADH enhances urinary concentrating capacity more than an
equivalent acute dose, by accentuating medullary water extraction; (2)
Improved Na conservation in chronic rats may be due in part to
stimulation of tubular Na reabsorption by long-term ADH.
The proteinuria in analgesic nephropathy (AN) is glomerular. R.S.
Nanra, S.K. Nanra, Department of Nephrology, Royal Newcastle
Hospital, Newcastle, N.S. W., Australia. The pattern of proteinuna was
studied in 10 AN patients and 10 glomerulonephritis (ON) patients with
proteinuria >0.5 g/day, the AN and GN groups being matched for GFR
(53 SD 37 mI/mm). Urine and serum concentrations of IgG, albumin and
acid glycoprotein (AGP) were measured by partigen plates, and beta-
2-microglobulin (B2M) by RIA from which the sieving coefficients (SC)
of these proteins were calculated. The ratios in urine of glomeru-
lar/tubular protein (GTPR) and IgG/transferrin (as an index of glomer-
ular protein selectivity) were measured by polyacrylamide gel electro-
phoresis. The ratio of albumin/B2M in urine was higher in ON compared
to AN patients (P < 0.05); the GTPR in GN patients (2.6 SD 1.8) was
higher than in AN patients (1.22 SD 0.98) but the difference was not
significant (P < 0.1 > 0.05). No significant differences were seen by the
paired i-test, in serum B2M, UV albumin, U albumin/Cr, UV B2M, U
B2M/Cr, SC IgG, albumin, AGP and B2M, and ratio of UIgG/transfer-
rin. Concusion: The proteinuria in AN is similar to that in GM and is
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therefore glomerular in origin. (GFR = calculated Creatinine clear-
ance.)
Lisinopril pharmacokinetics in chronic renal failure. B. Jackson, R.
Cubela, CI. Johnston, Melbourne University, Department of Medi-
cine, Austin Hospital, Heidelberg, VictOria, Australia, Lisinopril
(MK521) is an angiotensin converting enzyme (ACE) inhibitor that does
not require bioactivation and is not metabolized in vivo, thus having
potential advantages for use in chronic renal failure. Eight patients with
stable chronic renal failure (creatinine clearance 0.22 tO 1.1 mI/see)
were treated with 5 mg lisinopril (P.O.) daily for one week, and acute
and chronic pharmacokinetics studied. Peak plasma concentrations of
lisinoprii were observed 8—12 hours after the initial dose. Steady-state
plasma lisinopril concentrations were reached 3 to 5 days later There
was a close inverse correlation between plasma lisinopril concentration
and creatinine clearance (r = 0.88, P < 0.01). Plasma angiotensin
converting enzyme activity was inhibited in proportion to plasma
lisinopril concentration (r = 0.99, P < 0.001). Calculated in vivo 1C50
was 42 6 ng lisinopril/ml. Renal function remained stable over the one
week of treatment. Urinary protein excretion was reduced in the two
patients with significant proteinuria. Plasma K rose from 4.3 0.2 to
4.9 1.9 (P = 0.05). We have developed a novel assay system
(radioinhibjtor binding displacement [RIBD]) for measurement of ACE
inhibitors, to avoid the need to develop new radioimmunoassays (RIA)
for individual angiotensin converting enzyme inhibitors. Results were
compared between the RIA and RIBD for lisinopril. There was a close
concordance between results over the entire concentration range of
lisinopril (r = 0.95, N = 142, P < 0.001). The radioinhibitor binding
displacement method can be used to assess the pharmacokinetics of any
competitive angiotensin converting enzyme inhibitor.
An episode of aseptic "peritonitis" in a CAPD unit. J. Moran, B.
Murphy, J. Andrew, J. Niall, St. Vincent's Hospital, Melbourne,
Australia. Since August 1986 there have occurred 14 cases of an
unusual "peritonitis" in 9 patients, 5 of the patients having 2 episodes
each. The syndrome is characterized by the absence or near-absence of
abdominal pain in the presence of cloudy dialysate return. The fluid
contains low numbers of white cells (range 19 to 1 ,960 x 106 per liter,
median 201). The differential white cell count in 5 of the 13 cases in
which it was performed showed 100% polymorphs; in the other 8 cases
lymphocytes were also present (8 to 90%). Eosinophils were Pever
seen. A Gram stain of the dialysate was negative in all cases. Culture
was negative in all except one case in which the fluid grew staph
epidermidis from the enrichment broth—a probable contaminant. All
cases resolved rapidly, with no antibiotics bejng given in 9 of the 14
episodes. The etiology of this syndrome is unknown. It is clearly not
culture negative peritonitis. The rapid resOluion often within a few
hours, suggests that it is due tO peritoneal irritation by an unknown
factor. However no biochemical abnormalities were demonstrable in
the dialysate. In patients presenting with cloudy dialysate containing
low numbers of White cells and without abdominal pain it is appropriate
to withhold antibiotics, observe the clinical course and await the results
of dialysate culture.
Continuous ambniatory peritoneal dialysis—A teaching hospital expe-
rience. CA. Pollock, L.S. Ibels, K. Heathcote, B. Cocksedge,
R.J.Caterson, J.F. Mahony, Department of Renal Medicine, Royal
North Shore Hospital, St. Leonards, N.S. W,, Australia. We wish to
report a teaching hospital's 6 year experience with CAPD from January
1981 to January 1987. During this time, 112 patients, aged 8 to 76 years
(mean 49) were trained (75F, 37M) and 6 were transferred from other
hospitals. Of these, 65 were removed froffi the program, 20 were
transplanted successfully, 15 died, 23 transferred to hemodialysis, 6
transferred to other units and one was able to discontinue dialysis.
Temporary hemodialysis Was instigated 50 times during the 6 years, the
major reasons being peritonitis, tunnel infections, hernias or subcuta-
neous leaks. Twenty-nine patients were transferred from hemodialysis
to CAPD, the major reasons being cardiac disease, difficulties with
access and the psychosocial aspects of hemodialysis. The peritonitis
rate showed a progressive improvement from one episode every 4
months at the end of 1981 to 1 episode every 14.5 months, with the
majority occurring in patients on CAPD for less than 12 months.
Sixty-five catheters needed replacement, the commonest causes being
to reinstigate CAPD after temporary hemodialysis, or omental wrap-
ping around the catheter. Rehabilitation was regarded as excellent by
the majority of patients as most were working full or part time, or able
to work but retired. We therefore conclude that CAPD is an acceptable
form of treatment but must be considered an integral part of treatment
in any renal replacement program.
Renal biopsy in children. R.R. Bailey, K.L. Lynn, 5.1. Gorrie,
Department of Nephrology, Christchurch Hospital, Christchurch, New
Zealand. Percutaneous renal biopsy has become increasingly used for
assessing prognosis, monitoring progress and allowing a more rational
approach to the therapy of a wide range of renal diseases. In this study
we have reviewed our experience with renal biopsy in children. From
Jan. 1973 to Dec. 1986 all children under 16 years undergoing renal
biopsy have been followed prospectively. Thirty-one boys (mean age
10.5 yr; SD 3.4) and 15 girls (mean age 12 yr; SD 2.2) had a total of 57
biopsies. Indications for biopsy: nephrotic syndrome (12) [steroid
responsive, frequent relapsing 8; steroid resistant 3, congenital 1],
macroscopic hematuria (11), Henoch SchOnlein purpura (9), SLE (4),
persistent microscopic hematuria (3), proteinuria (2), nephntic-ne-
phrotic syndrome (2), reflux nephropathy, proteinuria and renal failure
(2), malignant hypertension and renal failure (1). The histological
diagnoses were Henoch SchOnlein nephritis (9), IgA nephropathy (6),
minimal change nephropathy (6), normal renal morphology (5), lupus
nephritis (4), focal glomerulosclerosis (3), Alport's syndrome (2) and
miscellaneous (10). lii 3 children inadequate tissue was obtained at the
first attempt and was repeated in 2. Eight biopsies were followed by
macroscopic hematuria, 2 of these developed a renal hematoma and
another clot co1ic From the successful biopsies a mean of 22 (2—70)
glomeruli were Obtained for light microscopy, while tissue taken for
immuriofluorescence was adequate in 89% and for electron microscopy
in 94%. Renal biopsy by an experienced nephrologist using ultrasonic
control andhaving ihe facilities of an expert histopathological service is
a safe and valuable diagnostic aid for children with a wide range of renal
disorders.
The use of a protein excretion index (PEI) as a predictor of 24 houL
urinary protein excretion (24 UPE). M.B. Fraenkel, L,J. Barratt, M.
Peake, M. Pejakovic, Flinders Medical Centre, Adelaide, South Aus-
tralia, Auytralia. It has recently been suggested that a reliable estimate
of 24 UPE can be obtained by deriving a PET based on the
protein: creatinine concentration ratio in a spot urine specimen: (mg
protein/liter) divided by (mmol creat/liter). This proposal was investi-
gated in two groups of patients: Group I comprised 20 inpatients
providing 23 x 24 hour urine specimens. Group H comprised 41
outpatients providing 45 X 24 hour specimens. In Group I each voided
specimen over the 24 hour period was collected and analyzed sepa-
rately. Measurement of 24 UPE (y) was plotted against the PEI (x)
obtained On spot urine specimens collected during or immediately after
the 24 hour collection; correlations were sought by linear regression
analysis. In Group I a line of equation y = 8.lx —74 with an r value of
0.857 (P < 0.001) was obtained, while in Group II, y = 6.4x + 972 with
an r value of 0.783 (P < 0.001). The significant r value suggesting a good
correlation between 24 UPE and PEI for both groups is misleading.
Further analysis within individual patients of Group I revealed a large
variation in PEI between separate spot specimens. The PEI varies from
l6—299% of the mean value and thus on many specimens would have led
to both under and over-estimation of the 24 UPE. Conclusiom The PEI
has limitations as a predictor of 24 UPE and should be used with caution
to avoid inappropriate investigation and management in some patients.
Use of 1-deamino-8-D-arginine-vasopressln (DDAVP) In correcting
prolonged bleeding time in uremia. M.D. Fraenkel, L.J. Barratt, A.S.
Gallus, Flinders Medical Centre, delaide, South Australia, Australia.
Although precise mechanisms underlying uremic bleeding are not fully
understood, cryoprecipitate, DDAVP and conjugated estrogens have
been reported to correct the bleeding disorder, The best predictor of
clinical bleeding is thought to be skin bleeding time (SBT) (normal <7
minutes). Over an 18 month period an SBT was performed on all
patients with chronic renal failure prior to undergoing a surgical
procedure or angiography (79 occasions). DDAVP was administered
prophylactically on 10 occasions when SBT was greater than 15 minutes
(normal platelet count, no oral antiplatelet agents). Reduction in SBT to
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10 4 minutes was achieved with a single i.v. dose 0.4 mcg/kg) in 8
patients with no adverse effects. There were no penoperative bleeding
complications. One patient failed to respond to a single i.v. dose, but on
another occasion SBT fell from >20 minutes to 9 minutes when 2
further doses (1.3 mcg/kg) were administered intranasally (IN). This
patient had previously presented with menorrhagia, and administration
of IN DDAVP twice daily for 5 days was associated with cessation of
bleeding and sustained correction of SET from >20 minutes to <7
minutes allowing adequate preparation for hysterectomy, Hyponatre-
mia (serum Na 121 mmol/l) developed on Day 3 of this regimen. Three
further patients with normal or mildly impaired renal function also
responded to DDAVP with SET falling to less than 10 minutes.
Conclusion: In uremic patients DDAVP administered by intravenous or
intranasal route is safe and effective in reducing skin bleeding time.
The single kidney—Agenesis vs. nephrectomy. B. U. Ihie, M. El-
Khatib, G.J. Becker, P.S. Kincaid-Smith, Department of Nephrology,
Royal Melbourne Hospital, Melbourne, Australia. Focal glomerular
sclerosis (FGS) is now regarded as one consequence of loss of renal
mass. We postulated that the greater capacity of the foetal kidney for
subsequent hypertrophy and adaptation should make FGS more likely
in the remnant kidney as a result of unilateral renal agenesis (URA) than
after nephrectomy (Nx). Renal biopsies from 17 patients (F = 7, M =
10) with single kidneys, proteinuria and/or impaired function (mean age
44 15 years) were reviewed. Seven had had a Nx. The mean time
from Nx to biopsy was 23 8 years. Mean plasma creatinine concen-
tration (Cr) was 0.3 0.2 (range 0.13—0.85) mmolfliter and protein
excretion 2.6 2 gm124 hours. The proportion of scierosed glomeruli
was 35 18% (11—73%). There was a correlation between % sclerosed
glomeruli and Cr (r = 0.87, P <0.001). When URA were compared with
Nx patients the URA had worse renal function. The finding of worse
function in patients with URA than Nx has implications for long-term
morbidity in renal donors and patients with single kidneys.
Ascitic ultrafiltration in treatment of intractable ascites. K.N. Lai,
I. W.C. Leung, R. Swaminathan, Departments of Medicine and Chem-
ical Pathology, Chinese University of Hong Kong, Hong Kong. The
clinical efficacy of ultrafiltration (UF) of ascitic fluid with haemofilter in
the treatment of intractable ascites associated with chronic liver disease
or intra-abdominal malignancy was studied in 15 patients. The ascitic
fluid was reinfused into the peritoneal cavity after ultrafiltration. An
average of 6.2 liters of fluid was removed during 4.4 hours of ultrafil-
tration with no significant change in blood pressure, central venous
pressure, hemoglobin, platelets or plasma creatinine. Ascitic fluid
albumin rose significantly immediately after the procedure (from 5.2
4.3 g/liter to 31.9 30.0 g/liter P < 0.01). The plasma albumin
concentration increased significantly at the end of UF (P < 0.001). Also
there was a significant increase in urine output (P < 0.001), urinary
sodium excretion (P < 0.001), and endogenous creatinine clearance (P
<0.01) during the 48 hours following UF. There was no evidence of
hemodynamic, renal or hematological dysfunction, and other compli-
cations, including encephalopathy, peritonitis and variceal bleeding
were not experienced. Ultrafiltration of ascitic fluid with hemofilter may
be safely used in the temporary relief of refractory ascites due to
cirrhosis or intra-abdominal malignancy.
Nutritional status and amino acid reap. keto acid levels in patients
under optimum nutritional treatment (ONT) and on hemodialysis treat-
ment (RDT). K. Lindenau, K. Langer, K. Vetter, K.-H. Gotz, L. Meyer,
I. Kaschube, P.T. Frohling, Department of Internal Medicine, District
Hospital of Potsdam, Potsdam, GDR. The control of the nutritional
status is an important point in patients with chronic renal failure. In 50
patients on ONT (low protein diet plus keto acids) and 53 patients under
RDT, the nutritional status was investigated. Results were correlated to
the amino acid and keto acid pattern of the same patients. Albumin,
transferrin, the complete amino acid pattern and the branched chain
keto acids served as biochemical parameters. The nutritional status was
completed by absolute lymphocytic count, cutan test and anthropo-
metric investigations. Results of branched chain amino acids and keto
acids are:
KIVA KICA KMVA Val Leu lie
ONT 10.4 21.7 15.0 203 130 66
RDT 7.4 4.6 7.3 172 103 53
The immunological parameters and albumin were also significantly
lower in patients on RDT. No differences were found in the anthropo-
metric status. Loss of amino acids and glucose during the haemodialysis
is a catabolic stress for patients on RDT and is responsible for the
decreased immunological reaction. In patients on ONT a good nutri-
tional status can be preserved in spite of long-term treatment in
advanced renal failure.
Lead intoxication on the Sydney Harbour Bridge. C.A. Pollock, L.S.
Ibels, Department of Renal Medicine, Royal North Shore Hospital, St.
Leonards, N.S.W., Australia. Industrial lead intoxication is prevalent
and is often unrecognized due to the subtle early neuropsychiatric and
behavioral manifestations. Thirty-eight males (aged 20—62) who worked
on the Sydney Harbour Bridge for between 0.5 and 32 years were
assessed for lead intoxication. Eighteen were regarded as having lead
toxicity as assessed by symptoms suggestive of lead intoxication and a
positive Calcium EDTA (Ca EDTA) chelation test (urinary excretion
2 smol lead in 3 days after 1 g Ca EDTA lvi). These patients had
worked for significantly greater times as iron workers or removing paint
and all had significantly greater neurological, constitutional and
musculoskeletal symptoms, compared with those who were non-toxic.
Blood and lead levels were significantly higher in patients with lead
intoxication although a significant overlap occurred between the toxic
and non-toxic groups, such that lead intoxication could be predicted if
blood lead levels were greater than 1.5 smol/liter and excluded if less
than 0.7 mo1/liter (95% confidence limits) although within these values
lead intoxication was possible. Renal function and abnormalities of
hemosynthesis were similar in the 2 groups. Treatment of the 18
patients using Ca EDTA resulted in marked symptomatic improvement.
No side effects were observed. We conclude that lead intoxication in
industry remains very prevalent with the earliest symptoms being
neuropsychiatric in nature. The diagnosis is best established using a Ca
EDTA chelation test. An excellent response to treatment can be
expected with little risk of adverse side effects.
Patterns of glomerulonephrltls associated with hepatitis B virus surface
antigenemia. K.N. Lai, F.M. Lai, K.W. Chan, J. Valiance-Owen,
Departments of Medicine and Morbid Anatomy, Chinese University of
Hong Kong, Hong Kong. The frequency of hepatitis B surface antigen
(HBsAg) was studied in the sera of 311 patients with various forms of
primary glomerulonephritis and 43 patients with lupus nephritis. HBs
antigenemia was detected in 69 of the 311 patients (22%) with primary
glomerulonephritis and this prevalence of HBsAg carrier was signifi-
cantly higher than that in the general population (P < 0.001). These
patients had no clinical or laboratory findings to suggest acute or
chronic liver diseases. A higher HBs antigenemia carrier rate was not
observed in patients with lupus nephritis. Three glomerulopathic enti-
ties—membranous nephropathy, IgA nephropathy, and mesangial pro-
liferative glomerulonephntis—were found to be associated with a
higher prevalence of HBs antigenemia as compared with the general
population (P < 0.001). Glomerular deposits of HBsAg and/or hepatitis
core antigen (HBcAg) were detected in 41%, 61%, and 60% of renal
biopsy specimens from patients with membranous nephropathy, IgA
nephropathy, and mesangial proliferative glomerulonephritis associated
with persistent HBs antigenemia, respectively. During the mean study
period of 40 months (range 12—180), 14% of these patients with hepatitis
associated glomerulonephritis developed progressive renal deteriora-
tion; despite this none of them required maintenance dialysis therapy.
Our study suggests that hepatitis B virus antigenaemia may play a
significant pathogenetic role in the development of specific forms of
glomerulonephritis and these hepatitis B virus associated glomerulo-
nephritides can run an indolent but relentless and slowly progressive
clinical course.
Predictors of outcome of glomerulonepluitis (GN)—.A multivariate
stepwise discriminant analysis. R.S. Nanra, Department of Nephrology,
Royal Newcastle Hospital, Newcastle, United Kingdom. Two hundred
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and twenty-one biopsy-proven GN patients, mean age 31.2 so 17,2
years, with a mean follow-up of 38.2 SD 26.5 months (minimum 6
months), were analyzed. 27.6% of patients deteriorated, 47.5% re-
mamed stable, and 24.9% improved. The significant prognostic predic-
tors of renal deterioration, in order of maximum discriminant function,
were: initial GFR (P < 0.001), initial serum albumin (P < 0.001), mean
serum urate (P < .001), final proteinuria (P < .001), age (P < .001), BP
(P < 0.001), biopsy diagnosis (P < 0.005), persistent microscopic
hematuria (P < 0.01), specific treatment (P < 0.05) and initial micro-
scopic hematuria (P < 0.05). The biopsy diagnoses, in order of poor
prognosis were: Focal glomerular sclerosis, mesangiocapillary GN
Type I, mesangiocapillary ON Type II, crescentic GN, membranous
nephropathy, focal proliferative ON, mesangial proliferative GN and
endocapilary GN. Conclusions: (1) With proper management <30% of
GN patients may deteriorate, (2) management directed at normalization
of serum urate, BP and proteinuria may improve the outcome of GN
patients, and (3) the important clinical markers of poor prognosis in GN
are: reduction in initial GFR, persistent proteinurialnephrotic syn-
drome, hypertension, hyperuricemia and persistent microscopic hema-
tuna.
Monoclonal antibodies (McAbs) to non-glomerular basement mem-
brane (GUM) glomerular capillary wall (GCW) antigens In the rat: II.
Further characterization. M.J. Nicol, J.H. Miller, T.J. Neale, Depart-
ment of Physiology, Victoria University of Wellington, and Wellington
School of Medicine, New Zealand. Recent studies have indicated the
importance of discontinuously represented non-GBM antigens in the
pathogenesis of glomerulonephritis (GN). We have previously reported
the production of nephritogenic McAbs reactive with such antigens in
rat glomeruli. All McAbs have produced a granular pattern of glomer-
ular immunofluorescence. This work has been extended to demonstra-
tion of non-renal reactivity of the nephritogenic McAbs SC5 and P117.
SC5 reacts with membrane antigen present in spleen, brain and liver;
P117 with small intestine and aorta. Paired radiolabel studies with SC5
(known to bind to glomerular proteins of 53, 120 and 175 Kd) and
non-specific MeAb 06, showed a specific binding of SC5 to kidney
(0.186 SD 0.036 tg/g) and spleen (0.182 so 0.109 1g/g). PH7, which was
also reactive with tubular brush border, bound to a 31 Kd protein by
immunoblotting. Immunogold electronmicroscopy has localized the
binding sites of SC5 and PH7 to epithelial and endothelial components
of the GCW. These investigations extend our studies of the antigenic
charatenistics of rat glomeruli and further demonstrate the potential role
of non-GBM GCW antigens in the pathogenesis of GN.
The effect of streptococcal nephritogenlc antigen on complement acti-
vation In vitro. B.A. Pussell, E. Riley, P. Peake, T. Karplus, J. Tapsell,
l.A. Cluirlesworth, Departments of Nephrology and Microbiology,
Prince Henry and Prince of Wales Hospitals, Sydney, Australia. A
streptococcal nephritogenic antigen (nephnitis strain associated protein
ENSAP]) was isolated from the supernatant of a pure culture of Group
A Streptococci (strain A307 from J. Zabniskie, Rockefeller University,
New York, U.S.A.) initially grown from a patient with post-streptococ-
cal acute glomenjlonephritis (PSGN). In vitro testing of the purified
NSAP showed it to be a potent streptokinase by its ability to generate
plasmin from plasminogen in a colourimetric assay using a plasmin-
specific synthetic tripeptide substrate. Purified NSAP had no effect, in
vitro, on complement as measured by total hemolytic activity, alterna-
tive pathway activity or generation of complement breakdown prod-
ucts, However when added to decomplemented sera from patients
convalescing from PSGN, NSAP caused activation of the classical
pathway but not the alternative pathway. A lesser effect was achieved
by commercial streptokinase. Using a solid phase radioimmunoassay,
serum from patients with various disorders and high titres of antibodies
to streptolysin 0 (ASO), deoxyribonuclease B (DNase B) and strepto-
kinase (SK) were tested for antibodies to NSAP. There was a significant
correlation between anti-NSAP and anti-SK (r = 0.72, P < 0.001) but
no correlation with anti-DNase B nor ASO. All 18 convalescent serum
samples from patients with biopsy-proven PSGN had antibodies to
NSAP, while there were only 5 positive in 22 patients with evidence of
streptococcal infection but without renal involvement. We conclude
that NSAP, a potent streptokinase, does not directly activate comple-
ment but requires interaction with antibody. The site of that interaction
is yet to be determined. In addition, antibodies to NSAP have been
demonstrated in the convalescent serum of all patients with PSGN but
only 23% of other patients with streptococcal infection.
Effect of doxazuain on renal hemodynaiuics of hypertensive patients
with renal failure. R.R. Bailey, L. Nairn, R.J. Walker, Department of
Nephrology, Christchurch Hospital, Christchurch, New Zealand.
Doxazosin is a quinazoline derivative with aj-adrenoreceptor antago-
nist properties similar to those of prazosin. However doxazosin has a
longer elimination half-like making it suitable for once daily adminis-
tration. A previous study in this department showed that the pharma-
cokinetic properties of doxazosin were not different in patients with
varying degrees of renal insufficiency compared with healthy normo-
tensive male volunteers. This study (two week washout; two week
single blind placebo phase; eight week open doxazosin treatment) was
undertaken to determine the safety of doxazosin in 8 hypertensive
patients with varying degrees of renal insufficiency (plasma creatinine
0.15-0.60 mmol/liter). Doxazosin was started in a dose of I mg q24 hr
and if indicated was increased every two weeks to a maximum dose of
8mg daily. Effective renal plasma flow (ERPF) and glomerular filtration
rate (GFR) were measured with a double isotope method using 1251
hippuran and 51Cr-EDTA, respectively. In all but one patient doxazosin
was successful in controlling the blood pressure. At the end of the
placebo period the mean (SE) ERPF was 1.80 (0.31) mI/sec and after
eight weeks treatment with doxazosin was 1.69 (0.31) mI/sec. The
respective GFR measurements were 0.50 (0.10) and 0.45 (0.08) mI/sec.
These mean changes were not statistically significant. Six of the eight
patients suffered minor side effects. In summary, doxazosin was an
effective antihypertensive agent and had no adverse effects on the renal
hemodynamics of patients with renal failure. The drug only needs to be
given once daily and could be introduced in a starting dose of 0.5 mg
after stabilization on a diuretic.
The effect of atenolol on the cardiovascular responses during exercise In
patients with mild hypertension. A. Gillin, P. Fletcher, J. Horvath, G.
Bautovich, B. Hutton, D. Tiller, Departments of Renal and Nuclear
Medicine, and the Halistrom Institute of Cardiology, Royal Prince
A'fred Hospital, Sydney, Australia. Previous studies have shown that
beta blockers will decrease exercise capacity and reduce cardiac output
response during exercise. In 14 patients (8 males) with mild hyperten-
sion (diastolic BP 101 7 mm Hg) the effect of maximum, semi-erect
bicycle exercise on cardiac performance and hemodynamics was ex-
amined in a randomized crossover design after 8 weeks on atenolol (100
mg/day) and placebo.
Rest Exercise
Placebo Atenolol Placebo Atenolol
Work watts — — 137 60 129 56
Heart rate 75 3 55 10 166 15 115 19*
beats/mm
Systolic BP 153 16 137 15* 230 30 207 29*
mm Hg
Ejection fraction % 54 6 55 9 59 8 58 12




30±13 30±12 27±8 28±14
Cardiac output
I/minim2
2.8 1.4 2.2 0.7 6.4 3.0 4.6 2.1
Data are mean so. P < 0.001 vs. placebo
At rest and at maximum workload, atenolol lowered blood pressure by
reducing heart rate and cardiac output. At maximum exercise,
workload was unchanged. Stroke volume, end-diastolic and end-systol-
ic volumes and ejection fraction response were similar to placebo.
However, the observed changes in cardiac performance were different
from those reported in nonmotensive individuals. In this group of
patients, atenolol has adequately controlled blood pressure without
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impairing exercise capacity, but the underlying changes in cardiac
performance seen in hypertensive patients have not been altered by this
period of treatment.
Hypertension preceding neonatal renal vein thrombosis. D. Lewis, V.
Vu, M. Mclver, Paediatric Renal Unit, Queen Victoria Medical Centre,
Melbourne, Australia. Two premature neonates with hypertension
before the demonstration of a renal vein thrombosis (RVT) are pre-
sented. Both needed intermittent ventilation for respiratory distress
syndrome (RDS). Hypertension—BP greater than 90/45—was detected
during routine monitoring. T.C., 32 weeks at birth, weighed 1480g. She
had severe RDS, persistent foetal circulation, recurrent pneumothora-
ces, "sick cell syndrome", pleural effusions and edema. Hypertension
was noted at 3 weeks and a RVT found by ultrasound 10 days later.
R,C., 34 weeks weighing 2075 g, needed ventilation for 5 days.
Vomiting at I week produced hyponatremia and dehydration. Hyper-
tension was noted on day 9, proteinuria and hematuria on day 11.
Ultrasound 6 days later showed a RVT extending into the IVC. In both
ultrasound was normal 3 days after the onset of hypertension. Plasma
remn was elevated in both. Hypertension was treated with captopril. In
both, hypertension preceded the detection of RVT. Previous reports
suggest the hypertension and RVT occur simultaneously. Hypertension
due to parenchymal ischemia from thrombosis in smaller veins may
antedate clinically detectable RVT.
An Initial evaluation of the instruments for clinical research (ICR)
ambulatory blood pressure system. R.N. Wyndham, G.J. Perry, M.L.
Mare!, J.R. Lawrence, J. Shaw, Renal and Hypertension Units,
Repatriation General Hospital, Sydney, Australia. The ICR Ambula-
tory Blood Pressure System (ABPS) is a portable, battery-powered
sphygmomanometer device intended for outpatient blood pressure (BP)
monitoring. We have performed an initial evaluation to test its accuracy
in subjects (1) at rest, and (2) during graded exercise, using a random-
zero sphygmomanometer (RZS) for comparison. (1) Fifty-one normal
and hypertensive subjects sat quietly at rest for 5 minutes. Four sets of
duplicate readings, 2 RZS and 2 ABPS were taken in random sequence
using the same arm on each occasion. BP tended to fall with repeated
observation, but there was no significant difference between any of the
4 readings. There were strong correlations between RZS and ABPS in
both systolic (r = 0.96) and diastolic (r = 0.89) BP. (2) Fourteen normal
subjects sat quietly for 5 minutes, then underwent 3 five-minute
exercise routines of increasing exertion, and finally lay supine for S
minutes. At the end of each phase BP was measured simultaneously on
opposite arms by RZS and ABPS, using a single reading on each
occasion. There were significant correlations between RZS and ABPS
in both systolic (r = 0.84) and diastolic (r = 0.70) BP. Some subjects
exhibited a large discrepancy between RZS and ABPS readings which
was not rate dependent. ABPS appears to measure BP accurately in
resting and ambulant subjects, although further evaluation in ambulant
subjects is required. The results suggest that it is suitable for ambula-
tory BP monitoring.
Morphological events associated with acute initiation of renin synthesis.
G. Barret, V. Morgan, S.L. Skinner, D. Alcorn, G. Ryan, Departments
of Physiology and Anatomy, University of Melbourne, Parkville,
Victoria, Australia. Mice were depleted of renin by 6 weeks of 9a
fiudrocortisone and renin content fell to <20% of the control value and
mRNA was decreased. Renin granules were decreased and were dense
and irregularly shaped with vacuoles inside the granule matrix.
Enalapril was administered and mRNA rose within 8 hours and there
was no further increase. Renal remn had an initial decrease and the first
detectable rise was 48 hours later and continued to rise for the next 8
days. Within 6 hours stacks of dilated granular endoplasmic reticulum
(GER) were present. Enlarged Golgi profiles with many more cisternae
were associated with small matrix-containing vesicles. Protogranules
were present in these areas, containing both homogeneous, crystalline
and vesicular matrices. Small and large granules were present within
the cytoplasm, as well as some lysosomes. Following 2 days of enalapril
treatment myoepitheioid cells contained medium sized, rounded gran.
ules. The most abundant organelles within the cytoplasm were dilated
GER and Golgi profiles. When furosemide was administered as well,
the appearance of the synthetic cytoplasm became extreme. Large
lakes of dilated GER were often found between stacks of less dilated
GER. Four to five Golgi profiles were commonly found in one region of
the cell with granular material detectable in small buds of endoplasmic
reticulum. Vesicles, protogranules and mature granules were also
present. It was not uncommon to find this activity within cells contain.
ing many myofilaments, indicating the 'turning on' of synthetic activity
in contractile cells. This study demonstrates a rapid increase in cell
activity when enalapril is given and a marked increase in granules
before renin content rose as detected by biochemical methods.
Glomerular tip lesion in nephrotic syndrome. B.P. Hurley, D.M.
Painter, Renal Unit, Royal Canberra Hospital, and Department of
Anatomical Pathology, Royal Prince Alfred Hospital, Sydney, Austra-
lia. Three patients presenting with the nephrotic syndrome were found
on renal biopsy to have characteristic features of the recently described
"glomerular tip lesion". These comprise adhesion of the glomerular tuft
to the Bowman's capsule just beside the origin of the proximal tubule,
with foam cells or hyaline or silver-stained material in the tuft at that
point. In most nephrons the epitheium of the first part of the proximal
convoluted tubule is also abnormal, showing small low basophilic cells.
Apart from the glomerular tip lesions, 2 of the patients showed
mesangiopathic changes and the third showed focal necrotizing changes
in glomeruli. All patients received a trial of steroid therapy for nephrotic
syndrome and none had complete remission, although in 2 proteinuria
diminished. Two patients had follow-up biopsies. The glomerular tip
lesion has now been described in association with a variety of glomer-
ular diseases causing nephrotic syndrome. The lesion does not at
present carry specific therapeutic or prognostic implications but pro-
vides an insight into the evolution of one form of glomerular segmental
sclerosis. Wider recognition of the lesion may enable a correlation to be
made with clinical outcome.
Renal biopsies in analgesic nephropathy (AN)—A clinicopathological
study. R.S. Nanra, Department of Nephrology, Royal Newcastle
Hospital, Newcastle, N.S.W., Australia. Renal biopsies were per-
formed in 62 AN patients with a mean GFR of 32 su 25 mI/mm. The
biopsy findings were (1) chronic interstitial nephritis (CIN) (100%),
acute interstitial nephritis superimposed upon CIN (1.6%); (2) global
glomerular sclerosis (GS) (90.2%), focal OS (27.9%), focal glomerular
hyalinosis (GH) (44.3%), hypertrophied glomeruli (29.5%), proliferative
lesions (GN) (9.8%) (including focal, mesangial and extracapillary
lesions) and membranous nephropathy (3.3%); (3) benign nephroscle-
rosis (BNS) (61.3%), malignant nephrosclerosis (MNS) (11.3%). One
patient with AN and nephrotic syndrome had minimal change disease.
Significant correlations were found between: hematuria and focal GS,
focal OH, MNS and proliferative GN; proteinuna and focal OH and
proliferative OH; mean BP and focal GS, BNS, proliferative ON and
glomerular hypertrophy. ConclusIons: (1) 14.5% of AN patients have
been shown to have associated 'primary' glomerular disease, (2) a renal
biopsy should be considered in AN patients with proteinuria or
dysmorphic microscopic hematuria. GFR = calculatedcreatinine clear-
ance.
Lithium nephrotoxicity in young rabbits. Ci. Roe, R.G. Walker, P.S.
Kincaid-Smith, Royal Melbourne Hospital, Melbourne, Australia. The
possibility of lithium-induced renal tubular cystic change occurring in
young rabbits is suggested by previous studies of lithium nephrotoxicity
in adult rabbits and young rats. This study was conducted to investigate
the effects of chronic lithium exposure in young rabbits. Eighteen
6-week old NZW rabbits—6 controls (C) and 12 treated (Li) (75—150
mmol LiC1/kg food aiming for a plasma lithium level of 0.5—1.0
mmol/liter)—were followed over 6 months. All rabbits had free access
to water. Weight was measured weekly, plasma lithium fortnightly and
serum creatinine monthly. Closed renal biopsy was performed at 6
months and distal tubule luminal area quantitated by digitization
(Hewlett Packard 9874A). Mean (± SD) plasma lithium concentration
was 0.70 (±0.13) mmol/liter for Li. There was no difference in weight or
creatinine either initially or after 6 months treatment between C and Li.
Distal tubule mean luminal area at 6 months was significantly greater for
Li (3.3 0.8 sq units) compared to C (1.5 0.6 sq units) (P < 0.001).
We conclude that young rabbits treated with lithium for 6 months
develop distal tubule dilatation not associated with deterioration in
renal function. More pronounced cystic transformation may follow
therapy continued over a longer period.
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Congenital magnesium and lithium-losing nephropathy. N. W. Boyce,
S.R. Holdsworth, N.M. Thomson, R.C. Atkins, Departments of
Nephrology and Medicine, Prince Henry's Hospital, Melbourne, Aus-
tralia. Magnesium deficiency states are unusual causes of acquired
hypokalemia. We report a kindred with congenital magnesium and
lithium losing nephropathy identified via investigation of an index case
(AFS) presenting with refractory hypokalemia (K4 2.4—2.9 mM/liter).
AFS had noted lethargy and easy fatiguability over several years.
Demonstrated hypokalemia had failed to respond to K supplementa-
tion (up to 14 g KCI per 24 hrs). 24 hr urine K excretion was
inappropriately elevated (69 mM) as was CI excretion (174 mM/liter).
There was a minor elevation of aldosterone secretion (37 nmol/day:
Na adjusted normal < 17 nmol/day). Plasma magnesium was low (0.34
to 0.40 mM/liter normal 0.65—1.30 mM/liter) with an inappropriate
urinary magnesium loss (4.34 to 5.82 mM/day: normal < 1 mM/day in
Mg depletion). Plasma lithium was unrecordably low < 0.10 mM:
normal 0.70—1.40 mM) with a high urinary lithium loss (2.48 to 4.13
mM/day). Renal function was otherwise normal. Therapy with oral
magnesium corrected the plasma magnesium deficit and normalized
plasma K and aldosterone secretion. Investigation of available family
members showed mother and brother to have hypomagnesemia with
renal magnesium wasting and low plasma lithium values with inappro-
priate urinary lithium excretion. No family member suffered hypokal.
emia. This kindred presents a previously undescribed syndrome of
congenital magnesium and lithium losing nephropathy. This disorder of
cation handling by the renal tubule, apparently inherited as an autoso-
mal dominant trait, suggests linkage of the transport mechanisms for Li
and Mg tubular absorption.
Familial normotensive, hypokalenuc, hyperreninemle hyperaldoateron-
lam with meduftary nephrocalcinosls despite normal urinary calcium
excretion—A unique 'variant of Bartter's Syndrome? N.W. Boyce, S.R.
Holdsworth, D. Hooke, P. Kerr, N.M. Thomson, R.C. Atkins, Depart-
ments of Nephroloy and Medicine, Prince Henry's Hospital, Mel-
bourne, Australia. Hypokalemic alkalosis in association with hyperre-
ninemia, hyperaldosteronism, normotension and hyperplasia of the
juxtaglomerular apparatus (Bartter's syndrome) is the major cause of
congenital potassium (Ki wasting. Two siblings with a unique variant
of Bartter's syndrome presenting with symptomatic hypokalemia and
urinary calculi are described. Both demonstrated hyperreninemia
(plasma ream concentration >100 units: normal <12 units) and
hyperaldosteromsm (24 hr urinary aldosterone excretion >600 nmol:
Na adjusted normal <17 nmol) despite sodium loading. Both demon-
strated bilateral medullary nephrocalcinosis with pyelographic evidence
of collecting duct ectasia. Their urinary calcium excretions were
repeatedly within normal limits (<3.0 mai/24 hrs: normal 2.0—7.5 mssI24
hrs). Renal function has remained normal in both siblings over a 6 year
follow-up period (CrC!> 1.8 ml/sec/1.73 m2). Treatment with oral K
supplementation (in doses up to 12 g124 hrs) or combined
spironolactone/K supplementation failed to adequately correct the
hypokalemia. Therapy with prostaglandin synthetase inhibitors also
failed to correct the plasma K deficit. Amioride therapy normalized
plasma K in both. These siblings present a previously undescribed
complex of familial, normotensive, hyperreninemic hyperaldosteronism
with normocalcemia, a normal urinary calcium excretion and medullary
nephrocalcinosis. The relationships between this syndrome, classic
Bartter's syndrome and other similar hereditary potassium wasting
disorders will be highlighted.
The use of damaged kidneys In living donor transplantations. P.1.
Little, J.P. McMullin, W. Mansson, A. Macdonald, Ibn Al Bitar
Hospital, Baghdad, Iraq. In many areas, live donors form the only
source of kidneys for transplant. It is usually a prerequisite that the
donor is medically fit and has two normal kidneys, one of which can be
the donor organ. In a series of 175 live donor transplant operations,
there were two in which the donor kidney was damaged. The first was
a girl aged 14. The only ABO compatible family donor was a sister of 21.
Investigation showed that this girl had unilateral refiux nephropathy.
Eighteen months later the family requested further consideration of the
use of the damaged kidney to allow respite from dialysis. The donor was
normotensive with normal renal function. The damaged kidney mea-
sured 9 cm x 3.5 cm on IVU but only 6 cm x 3.5 cm at nephrectomy.
It was transplanted and functioned immediately. There were 2 rejection
episodes and a minor urine leak which cleared after 19 days. At 6
months post-transplant the donor had an Scr of 84 anolIliter and the
recipient 162 1Lmol/liter. Hypertension was a problem only in the early
post-transplant period. The second patient was a woman aged 51,
whose husband—a cousin—volunteered to donate a kidney which had
previously had stone surgery. He was mildly hypertensive and IVU
showed a scarred right kidney. His renal function was normal. The
recipient was given two donor-specific transfusions and transplanted
two weeks later. The kidney was adherent to perinephric fat which
could not be dissected away. Transplant function was immediate, but
there was considerable serous and lymphatic ooze for 20 days. Hyper-
tension persists in the recipient. After 3 weeks the Sc of the recipient
was 98 mol/liter and of the donor 105 pmol/liter. His B.?. was 120/70.
It is suggested that organs removed for clinical reasons may sometimes
by suitable for transplantation.
Causes of graft loss In renal transplant recipients managed with
cyclosporin A. E. Savdie, J.M. Hayes, M. Ralston, Renal Unit and
Department of Anatomical Pathology, St. Vincent's Hospital, Sydney,
Australia. Since October 1984, twenty-five consecutive recipients of
cadaver grafts (20 first, 4 second and 1 third) have been managed with
short-term cyclosporine A and low-dose prednisolone. As at December
1986, there had been no deaths. There were 5 graft losses, all within the
first 3 months, so that the actuarial graft survival was 79% at 3, 6, 12,
and 24 months. One graft came from a donor who, in retrospect, had
disseminated intravascular coagulation; the graft became blue and soft
after re-anastaniosis in the recipient and was removed. Two grafts were
lost within 72 hours due to graft vein thrombosis, of the main renal vein
in one case and the renal vein tributaries in the other. One recipient had
a coagulopathy post transplant and lost his graft because of hemorrhage
around and beneath the renal capsule and around the penureteric
venous plexus, which was thrombosed. In only one case was graft loss
due to rejection, predominantly vascular, at 3 months. These results
indicate that, in patients managed with cyclosponne A, rejection is not
a major cause of graft loss and that cyclosporine-related thrombosis
may be the most important.
